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Abstract 
 
Objectives  
 
The aim of this hospital based study, which was conducted in Gadaref town, 
Republic of Sudan, was comparison between the efficiency and safety of sodium 
stilbogluconate (SSG) alone and in combination with fluconazole (FL.) in the 
treatment of visceral leischmaniasis (VL) in Gadaref Teaching Hospitals. 
  
Methodology 
Between June 2005 and August 2007, 44 patients were selected with complaints of 
fever and other symptoms, VL was diagnosed clinically and approved 
parasitologicaly in all of them, and they met the inclusion criteria for this hospital 
based study. 22 Patients were appropriately recruited and randomly allocated to 
either the SSG treatment (20 mg/kg/day for 3o days); the other 22 patients were 
randomly allocated to combination therapy of FL. (150 mg /day for 30 days) and 
SSG (20 mg/kg/day for 3o days) with high follow up rate in various conditions.  
Clinical examination was carried out on admission and repeated on day 7, 14, 21 
and 30 of treatment for all VL patients, which include complaints (headache, GIT 
symptoms, UT symptoms, RT symptoms, epistaxis.); history (drug history, disease 
history, liver history, renal history); general examination (fever, pale, jaundice); 
abdominal examination (spleenomegaly; hepatomegaly); cardiovascular 
examination (arrhythmia).  
Parasitological investigations including gland puncture test, bone marrow aspirate  
test or spleen puncture test were carried out on admission and repeated on day 7, 
14, 21 and 30 of treatment for all VL patients.  
Biochemical investigations which include liver function test, Blood urea, Hb% and 
TWBC were also carried out before, throughout and after treatment for all VL 
patients.  
Chest x-ray and ECG were done on admission and repeated on day 15 and 30 of 
treatment for all patients. 
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All patients were weighed on admission and at day 7, 14, 21 and 30 of treatment 
The comparison between the efficiency and safety of the two treatment regiment 
against VL based on different parameters and variants including, clinical 
improvement (improvement of clinical signs and symptoms like weight gain, spleen 
size reduction, liversize reduction and patient's recovery and general condition), 
biochemical and hematological test improvement (increase in Hb% and white blood 
cell count). parasitological cure, side effect and mortality rate. 
Result 
As a result, it was found that there was no signifsicant differences  in clinical 
improvement, biochemical and hematological test improvement, parasitological 
cure, side effect  and mortality rate between  the treatment of VL using combination 
therapy of FL. at a dose of 150 mg /day for 30 days and SSG at a dose of 20 
mg/kg/day for 3o days and the standard treatment of VL using SSG alone in a dose 
of 20mg/kg/day for 30 days. 
Conclusion 
The combination therapy of FL. and SSG against visceral leischmaniasis had no 
significant advantages over the single drug SSG, and there would be no change in 
the duration of treatment, resistance management, overall cost of treatment and 
hospitalization period. 
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  اﻷﻃﺮوﺣﺔﺺ ﺴﺘﺨﻠﻣ
 
  ﺍﻻﻫﺩﺍﻑ    
ﺍﻟﻐﺭﺽ ﺍﻻﺴﺎﺴﻰ ﻤﻥ ﻫﺫﺍ ﺍﻟﺒﺤﺙ ﺍﻻﻜﻠﻴﻨﻴﻜﻲ ﺍﻟﺫﻯ ﺘﻡ ﺍﺠﺭﺍﺅﻩ ﺒﻤﺴﺘﺸﻔﻰ ﺍﻟﻘﻀﺎﺭﻑ ﺍﻟﺘﻌﻠﻴﻤـﻰ            
 ﻓﻌﺎﻟﻴﺔ ﺩﻭﺍﺀ ﺼﻭﺩﻴﻭﻡ ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ ﻟﻭﺤـﺩﻩ ﻭﻓﻌﺎﻟﻴـﺔ ﺒﻤﺩﻴﻨﺔ ﺍﻟﻘﻀﺎﺭﻑ ﻓﻰ ﺍﻟﺴﻭﺩﺍﻥ  ﻫﻭ ﺍﻟﻤﻘﺎﺭﻨﻪ ﺒﻴﻥ 
  .ﻓﻠﻭﻜﻭﻨﺎﺯﻭل ﻤﻌﺎ ﻓﻰ ﻋﻼﺝ ﻤﺭﺽ ﺍﻟﻜﻼﺯﺍﺭ ﺍﻟﺤﺸﻭﻯﻭﺍﻟﺩﻭﺍﺀ ﺍﻟﺜﻨﺎﺌﻰ ﺼﻭﺩﻴﻭﻡ ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ 
  ﻤﻨﻬﺠﻴﺔ ﺍﻟﺒﺤﺙ
( 44)ﻡ ﺘﻡ ﺍﺨﺘﻴﺎﺭ ﻋﺸﻭﺍﺌﻰ ﻟﻌﺩﺩ 7002 ﻭﺤﺘﻰ ﺍﻏﺴﻁﺱ ﻤﻥ ﻋﺎﻡ 5002ﻓﻰ ﺍﻟﻔﺘﺭﻩ ﻤﻥ ﻴﻭﻨﻴﻭ ﻤﻥ ﻋﺎﻡ ﻡ  
ﻭﺘﻡ ﺘﺸﺨﻴﺹ ﻤﺭﺽ ﺍﻟﻜـﻼﺯﺍﺭ ﺍﻟﺤـﺸﻭﻯ ﻋـﻥ ، ﺭﻀﻴﻪ ﺍﺨﺭﻯ ﻤﺭﻴﺽ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺍﻟﺤﻤﻰ ﻭﺍﻋﺭﺍﺽ ﻤ 
ﺍﻨﻁﺒﻘﺕ .  ﻟﺠﻤﻴﻊ ﺍﻟﻤﺭﻀﻰ ﻁﺭﻴﻕ ﺍﻟﻜﺸﻑ ﺍﻻﻜﻠﻴﻨﻴﻜﻰ ﻭﺘﻡ ﺘﺎﻜﻴﺩ ﺍﻟﺘﺸﺨﻴﺹ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻔﺤﺹ ﺍﻟﺠﺭﺜﻭﻤﻰ 
  . ﺒﺎﻟﻤﺴﺘﺸﻔﻰﻋﻠﻰ ﻫﺅﻻﺀ ﺍﻟﻤﺭﻀﻰ ﻤﻌﺎﻴﻴﺭ ﺍﻻﺨﺘﻴﺎﺭ ﻟﻬﺫﺍ ﺍﻟﺒﺤﺙ ﺍﻻﻜﻠﻴﻨﻴﻜﻰ
 ﺩﻭﺍﺀ ﺼـﻭﺩﻴﻭﻡ ﻋـﺸﻭﺍﺌﻴﺎ ﻻﺴـﺘﻌﻤﺎل ﺘﻡ ﺍﺨﺘﻴـﺎﺭﻫﻡ ﺍﻟﻤﺭﻀﻰ ﻫﺅﻻﺀ  ﻤﻥ ﻤﺭﻴﺽ( 22)   ﻋﺩﺩ 
 ﺘﻡ ﺍﺨﺘﻴـﺎﺭﻫﻡ  ﻴﻥ ﺍﻻﺨﺭﻤﺭﻴﺽ( 22)ﻋﺩﺩ ﺍل  ﻭ (03ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ / ﻜﺠﻡ/  ﻤﻠﺠﻡ 02 )ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ ﻟﻭﺤﺩﻩ 
 ﻤﻊ (03ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ / ﻜﺠﻡ/  ﻤﻠﺠﻡ 02 ) ﻻﺴﺘﻌﻤﺎل ﺍﻟﻌﻼﺝ ﺍﻟﺜﻨﺎﺌﻰ ﺼﻭﺩﻴﻭﻡ ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ  ﻜﺫﻟﻙ ﻋﺸﻭﺍﺌﻴﺎ
ﺨﺘﻠﻑ ﺍﻟﻅﺭﻭﻑ ﺤﺘـﻰ ﻨﻬﺎﻴـﺔ  ﻭﻓﻰ ﻤ ﺠﻴﺩﺍﻭﺘﻤﺕ ﻤﺘﺎﺒﻌﺘﻬﻡ ، ( ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ ﺸﻬﺭ /  ﻤﻠﺠﻡ 051 )ﻓﻠﻭﻜﻭﻨﺎﺯﻭل
 .ﺍﻟﺒﺤﺙ
    ﺘﻡ ﺍﺨﻀﺎﻉ ﺍﻟﻤﺭﻀﻰ ﻟﻠﻔﺤﺹ ﺍﻻﻜﻠﻨﻴﻜﻰ ﻋﻨﺩ ﺩﺨﻭﻟﻬﻡ ﻟﻠﻤﺴﺘﺸﻔﻰ ﻭﺍﻋﻴﺩ ﺍﻟﻔﺤـﺹ ﻓـﻰ ﺍﻟﻴـﻭﻡ 
، ﺍﻟـﺼﺩﺍﻉ ) ﺍﻟﻭﺍﺤﺩ ﻭﺍﻟﻌﺸﺭﻴﻥ ﻭﺍﻟﺜﻼﺜﻴﻥ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﻌﻼﺝ ﻭﺍﺸﺘﻤل ﻋﻠﻰ ﺍﻟﺸﻜﻭﻯ ، ﺍﻟﺭﺍﺒﻊ ﻋﺸﺭ ، ﺍﻟﺴﺎﺒﻊ
ﻭﻋﻠﻰ ( ﺍﻟﺘﻨﻔﺴﻰ ﻭﻨﺯﻴﻑ ﺒﺎﻻﻨﻑ ﺍﻋﺭﺍﺽ ﺒﺎﻟﺠﻬﺎﺯ ، ﺍﻋﺭﺍﺽ ﺒﻤﺠﺭﻯ ﺍﻟﺒﻭل ، ﺍﻋﺭﺍﺽ ﺒﺎﻟﻘﻨﺎﺓ ﺍﻟﻬﻀﻤﻴﺔ 
ﻤﺜـل ) ﻭﻋﻠﻰ ﺍﻟﻔﺤﺹ ﺍﻟﻌﺎﻡ ( ﻭﺍﻟﻜﻠﻰ، ﺍﻟﻜﺒﺩ ، ﺍﻟﻤﺭﺽ ، ﻤﺜل ﺘﺎﺭﻴﺦ ﺍﻟﻌﻼﺝ ﺒﺎﻟﻌﻘﺎﻗﻴﺭ ) ﺘﺎﺭﻴﺦ ﺍﻟﻤﺭﻴﺽ 
ﺘـﻀﺨﻡ ) ﻭﻜﺫﻟﻙ ﻋﻠﻰ ﺍﻟﻔﺤﺹ ﺍﻟﻤﻌـﻭﻯ ( ﺸﺤﻭﺏ ﺍﻟﺠﺴﻡ ﻨﺘﻴﺠﺔ ﻟﻔﻘﺩﺍﻥ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻭﺍﻟﻴﺭﻗﺎﻥ ، ﺍﻟﺤﻤﻰ 
  (.ﻘﻠﺏﺍﻀﻁﺭﺍﺏ ﻀﺭﺒﺎﺕ  ﺍﻟ) ﻭﻓﺤﺹ ﺍﻟﺠﻬﺎﺯ ﺍﻟﺩﻭﺭﻯ ( ﺍﻟﻁﺤﺎل ﻭﺍﻟﻜﺒﺩ
ﺍﺨﺘﺒﺎﺭ ﻨﺨﺎﻉ ﺍﻟﻌﻅﻡ ﺍﻭﺍﺨﺘﺒـﺎﺭ ﺍﻟﻁﺤـﺎل ﺍﻟﺘـﻰ  ،     ﺍﺸﺘﻤل ﺍﻟﻔﺤﺹ ﺍﻟﺠﺭﺜﻭﻤﻰ ﻋﻠﻰ ﺍﺨﺘﺒﺎﺭ ﺍﻟﻐﺩﺓ 
، ﺍﻟﺨـﺎﻤﺱ ﻋـﺸﺭ ، ﺍﺨﻀﻊ ﻟﻬﺎ ﺍﻟﻤﺭﻀﻰ ﻋﻨﺩ ﺩﺨﻭﻟﻬﻡ ﻟﻠﻤﺴﺘﺸﻔﻰ ﻭﺍﻋﻴﺩ ﻟﻬﻡ ﺍﻟﻔﺤﺹ ﻓﻰ ﺍﻟﻴﻭﻡ ﺍﻟـﺴﺎﺒﻊ 
  . ﺍﻟﻭﺍﺤﺩ ﻭﺍﻟﻌﺸﺭﻴﻥ ﻭﺍﻟﺜﻼﺜﻴﻥ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﻌﻼﺝ
ﻓﻰ ﺍﺜﻨﺎﺀ ﻭﺒﻌﺩ ﺍﻟﻌﻼﺝ ﻭﺍﺸﺘﻤﻠﺕ ، ﻟﺠﻤﻴﻊ ﻟﻠﻤﺭﻀﻰ ﻗﺒل     ﻭﺍﺠﺭﻴﺕ ﺍﻟﻔﺤﻭﺼﺎﺕ ﺍﻟﻜﻴﻤﻴﺎﺌﻴﺔ ﺍﻟﺤﻴﻭﻴﺔ 
  .ﺘﺭﻜﻴﺯ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻭﺤﺴﺎﺏ ﻜﺭﻴﺎﺕ ﺍﻟﺩﻡ ﺍﻟﺒﻴﻀﺎﺀ، ﻨﺴﺒﺔ ﺍﻟﻴﻭﺭﻴﺎ ﻓﻰ ﺍﻟﺩﻡ ، ﻋﻠﻰ ﻓﺤﺹ ﻭﻅﺎﺌﻑ ﺍﻟﻜﺒﺩ 
 ) elozanoculf + matsotnep ( ypareht noitanibmoC sisainamhsiel larecsiV
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ﻓـﻰ ﺍﻟﻴـﻭﻡ ، ﻭﺍﺠﺭﻴﺕ ﻟﻠﻤﺭﻀﻰ ﺍﻴﻀﺎ ﺼﻭﺭﺓ ﺍﺸﻌﺔ ﻟﻠﺼﺩﺭ ﻭﺭﺴﻡ ﺍﻟﻘﻠﺏ ﻋﻨﺩ ﺩﺨﻭل ﺍﻟﻤﺴﺘـﺸﻔﻰ 
  .ﺍﻟﺨﺎﻤﺱ ﻋﺸﺭ ﻭﺍﻴﻭﻡ ﺍﻟﺜﻼﺜﻴﻥ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﻌﻼﺝ
ﺍﻟﻭﺍﺤﺩ ، ﺍﻟﺨﺎﻤﺱ ﻋﺸﺭ ،     ﻭﺘﻡ ﻭﺯﻥ ﺠﻤﻴﻊ ﺍﻟﻤﺭﻀﻰ ﻋﻨﺩ ﺩﺨﻭﻟﻬﻡ ﻟﻠﻤﺴﺘﺸﻔﻰ ﻭ ﻓﻰ ﺍﻟﻴﻭﻡ ﺍﻟﺴﺎﺒﻊ 
  .ﻭﺍﻟﻌﺸﺭﻴﻥ ﻭﺍﻟﺜﻼﺜﻴﻥ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﻌﻼﺝ
 ﺍﻟﻨﻭﻋﻴﻥ ﻤﻥ ﺍﻟﻌﻼﺝ ﺍﻟﺘﻰ ﺘﻡ ﺍﺴﺘﻌﻤﺎﻟﻬﺎ ﻟﻌﻼﺝ ﻤﺭﻀـﻰ  ﻭﺍﻤﺎﻥ  ﺍﻟﻤﻘﺎﺭﻨﻪ ﺒﻴﻥ ﻓﻌﺎﻟﻴﺔ     ﻭﻗﺩ ﺍﺠﺭﻴﺕ 
ﺘﺤﺴﻥ  )  ﺘﺤﺴﻥ ﺤﺎﻟﺔ ﺍﻟﻤﺭﻴﺽ ﺍﻻﻜﻠﻴﻨﻴﻜﻴﻪ ﺕﺸﻤﻠﻭﻤﺘﻐﻴﺭﺍﺕ ﻤﺘﻌﺩﺩﻩ  ﺍﻟﻜﻼﺯﺍﺭ ﻓﻰ ﻫﺫﺍ ﺍﻟﺒﺤﺙ ﻋﻠﻰ ﻤﻌﺎﻴﻴﺭ 
ﻨﻘﺼﺎﻥ ﺤﺠـﻡ ، ﻨﻘﺼﺎﻥ ﺤﺠﻡ ﺍﻟﻁﺤﺎل ، ﺍﻟﻌﻼﻤﺎﺕ ﺍﻻﻜﻠﻴﻨﻴﻜﻴﺔ ﻭﺍﻻﻋﺭﺍﺽ ﺍﻟﻤﺭﻀﻴﺔ ﻤﺜل ﺍﻜﺘﺴﺎﺏ ﺍﻟﻭﺯﻥ 
) ﻭﺘﺤﺴﻥ ﻓﺤﻭﺼﺎﺕ ﺍﻟﺩﻡ ﻭﺍﻓﺤﻭﺼﺎﺕ ﺍﻟﻜﻴﻤﻴﺎﺌﻴﺔ ﺍﻟﺤﻴﻭﻴـﺔ ( ﻭﻜﺫﻟﻙ ﺸﻔﺎﺀ ﺍﻟﻤﺭﻴﺽ ﻭﺤﺎﻟﺘﻪ ﺍﻟﻌﺎﻤﺔ ، ﺍﻟﻜﺒﺩ 
،   ﺍﻻﺴﺘﺌـﺼﺎل ﺍﻟﺠﺭﺜـﻭﻤﻰ ﺍﻀﺎﻓﺔ ﺍﻟﻰ ( ﺭﻴﺎﺕ ﺍﻟﺩﻡ ﺍﻟﺒﻴﻀﺎﺀ ﻤﺜل ﺍﻟﺯﻴﺎﺩﺓ ﻓﻰ ﻨﺴﺒﺔ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﻭﻋﺩﺩ ﻜ 
  .ﺍﻻﻋﺭﺍﺽ ﺍﻟﺠﺎﻨﺒﻴﻪ ﻭﻨﺴﺒﺔ ﺍﻟﻭﻓﺎﺓ
  ﺍﻟﻨﺘﺎﺌﺞ
ﺤﺴﺏ ﻨﺘﻴﺠﺔ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ ﺍﻻﻜﻠﻴﻨﻴﻜﻴﻪ ﺒﺎﻟﻤﺴﺘﺸﻔﻰ ﻓﻘﺩ ﺘﻡ ﺍﻟﺘﻭﺼل ﺍﻟﻰ ﺍﻨﻪ ﻟﻴﺱ ﻫﻨﺎﻟﻙ ﺍﻯ ﺍﺨﺘﻼﻑ          
، ﻴﻤﻴﺎﺌﻴﺔ ﺍﻟﺤﻴﻭﻴـﺔ  ﻭﺘﺤﺴﻥ ﻓﺤﻭﺼﺎﺕ ﺍﻟﺩﻡ ﻭﺍﻓﺤﻭﺼﺎﺕ ﺍﻟﻜ  ﺤﺎﻟﺔ ﺍﻟﻤﺭﻴﺽ ﺍﻻﻜﻠﻴﻨﻴﻜﻴﻪ ﺘﺤﺴﻥﺫﻭ ﺍﻫﻤﻴﻪ ﻓﻰ 
 ﺍﻟﻜﻼﺯﺍﺭ ﺍﻟﺤـﺸﻭﻯ ﻰ ﻤﺭﻀ ﻤﻌﺎﻟﺠﺔﺍﻻﻋﺭﺍﺽ ﺍﻟﺠﺎﻨﺒﻴﻪ ﻭﻨﺴﺒﺔ ﺍﻟﻭﻓﺎﺓ ﺒﻴﻥ ، ﺍﻻﺴﺘﺌﺼﺎل ﺍﻟﺠﺭﺜﻭﻤﻰ ﺩﺭﺠﺔ 
 ﻴﻭﻡ ﻤﻊ 03ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ / ﻜﺠﻡ/  ﻤﻠﺠﻡ 02ﺒﺎﺴﺘﻌﻤﺎل ﺍﻟﻌﻼﺝ ﺍﻟﺜﻨﺎﺌﻰ ﺼﻭﺩﻴﻭﻡ ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ ﺒﺠﺭﻋﻪ ﺘﻌﺎﺩل 
 ﻤـﺭﺽ ﺍﻟﻜـﻼﺯﺍﺭ ﺍﻟﺤـﺸﻭﻯ ﺒﻴﻥ ﻤﻌﺎﻟﺠـﺔ ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ ﺸﻬﺭ ﻭ /  ﻤﻠﺠﻡ 051ﻓﻠﻭﻜﻭﻨﺎﺯﻭل ﺒﺠﺭﻋﻪ ﺘﻌﺎﺩل 
 03ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ / ﻜﺠﻡ/  ﻤﻠﺠﻡ 02ﺼﻭﺩﻴﻭﻡ ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ ﻟﻭﺤﺩﻩ ﺒﺠﺭﻋﻪ ﺘﻌﺎﺩل ﺍﻟﻌﻼﺝ ﺍﻟﻘﻴﺎﺴﻰ ﺒﺎﺴﺘﻌﻤﺎل 
  .ﻴﻭﻡ
  ﺍﻟﺨﻼﺼﺔ
ﻌـﻼﺝ ﻤـﺭﺽ ﻟﺼﻭﺩﻴﻭﻡ ﺴﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ ﻤﻊ ﻓﻠﻭﻜﻭﻨﺎﺯﻭل ﻟﻤﺩﺓ ﺸﻬﺭ ﺍﺴﺘﻌﻤﺎل ﺍﻟﻌﻼﺝ ﺍﻟﺜﻨﺎﺌﻰ           
 ،  ﺼﻭﺩﻴﻭﻡ ﺴـﺘﻠﺒﻭﺠﻠﻭﻜﻭﻨﻴﺕ  ﺍﻟﻌﻼﺝ ﺍﻻﺤﺎﺩﻯ ﺘﻌﻤﺎلﺍﺴﻋﻠﻰ  ﺍﻫﻤﻴﻪ ﻟﻪ ﻤﻴﺯﺓ ﺫﺍﺕ ﻟﻴﺱ  ﺍﻟﻜﻼﺯﺍﺭ ﺍﻟﺤﺸﻭﻯ 
ﻭﻟﺫﻟﻙ ﻟﻴﺴﺕ ﻫﻨﺎﻟﻙ ﺘﻐﻴﻴﺭﺍﺕ ﻓﻰ ﻤﺩﺓ ﺍﻟﻌﻼﺝ ﻭﻋﻼﺝ ﺍﻟﻤﺭﺽ ﺍﻟﻤﻘﺎﻭﻡ ﻟﻠﺩﻭﺍﺀ ﻭﺍﻟﺘﻜﻠﻔﺔ ﺍﻟﻜﻠﻴﺔ ﻟﻠﻌﻼﺝ ﻭﻤـﺩﺓ 
  .ﺍﻟﻤﻌﺎﻟﺠﺔ ﺒﺎﻟﻤﺴﺘﺸﻔﻰ
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CHAPTER ONE 
 
INTRODUCTION AND LITERATURE REVIEW 
 
1- Overview of leischmania 
1.1- Leischmania in general 
1.1.1- Historical background 
Kala-azar(KA) is not a new disease. It first came to the attention of Western doctors in 1824 in Jessore, 
India, where it was initially thought to be a form of malaria. India gave kala-azar its common name, 
which is the Hindi for “black fever”, so called for the darkening of the skin on the extremities and 
abdomen that is a symptom of the Indian form of the disease (WHO: control of leischmaniasis; Report 
of WHO expert committee,1990:793).  
The agent of the disease was also first isolated in India by Scottish physician William Leishman, who 
first diagnosed the cause of the disease while serving with the British army in India in the early 1900s. 
and Irish physician Charles Donovan, working independently of each other. As they published their 
discovery almost simultaneously, the species was named for both of them, Leischmania Donovani. 
Archibadi in 1922 described an epidemic of Kalazar (KA) which occurred in the Garo hills of Assam in 
Saudi Arabia as far back as 1870.  
Cunningham recorded a similar disease that occurred in 1885, caused by a parasite which was later 
named Leischmania tropica, the causative agent of cutaneous leischmaniasis (CL).  
Nicolle in 1908 reported that mammals including dogs could act as reservoir hosts for the leischmania 
parasite.  
Swaminath et al. in 1942, proved using human volunteers that the leischmania parasite could be 
transmitted by the phlebotomus sand flies (WHO: control of leischmaniasis. Report of a WHO expert 
committee. 1990; 793). 
1.1.2-Leischmania parasite 
Leischmania  is a protozoa parasitic infection caused by Leischmania  species which are obligate 
intracellular parasites of mononuclear phagocytes as follows: 
1- Visceral leischmaniasis or KA is caused primarily by L. donovani, L. chagasi, or L. infantum.  
2- CL usually divided into  
    (a) Old World leischmaniasis caused primarily by L. tropica, L. major, L. aethiopica, and  
    (b) New World leischmaniasis caused primarily by L. Mexicana or L. braziliensis. Diffuse CL is 
caused primarily by L. aethiopica or L. mexicana.  
3- Mucocutaneous leischmaniasis (espundia) is caused primarily by L. (viannia) braziliensis.  
Altogether, there are about 21 leischmanial species that are transmitted by about 30 species of sand flies 
(Ashford RW, 1996). 
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1.1.3-Leischmania parasite transmission 
Leischmania parasite is transmitted through the bite of female sand flies insect (phlebotomine) (Figure 
1.1). 
 
 
 
Figure 1-1: a female sand fly insect  
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Humans, wild animals and domestic animals are known to act as reservoir hosts, In the human host,  
Lutzomyia logipalpis is the only sand fly vector that has been implicated in the transmission of the new 
world species of visceral leischmaniasis (WHO: expert committee report.1991; Shiddo et al, 1995; 
Arias et al, 1996). 
1.1.4-Leischmania epidemiology  
Leischmaniasis epidemiology is linked to poverty, economic development and various environmental 
changes such as deforestation, urbanization, migration of people into endemic areas and building of 
dams etc. (Thakur CP, Et al. 2004). 
Malnutrition is a predisposing factor for progression from KA infection to disease, and delays in 
diagnosis and treatment increase the risk of severe morbidity and mortality. Women and female 
children from poorer households in rural areas are likely to suffer from chronic energy deficiency or 
malnutrition, lower life expectancy, and higher rates of mortality and morbidity from illness because of 
limited healthcare access. Baseline nutrition status and other circumstances modify the effect of KA for 
women in poor rural communities (Mary Ann Liebert, 2004; Indu B. Ahluwalia, et al, 2004). 
In South America several studies examine what causes some people to develop disease, have 
documented clustering of the disease within families, and there seems to be a genetic contribution over 
an environmental one that explains the incidence of the disease (J. M. Blackwell, et al. 1997).  
1.1.5-Life-cycle of leischmania parasite 
KA is spread through an insect vector, the sand fly are tiny creatures 2-3 millimeters long and found in 
tropical or temperate regions throughout the world. Sand fly larvae grow in warm, moist organic matter, 
so old trees, house walls or garbage are their most common breeding centers, making them hard to 
eradicate. 
The adult female sand fly is a bloodsucker, usually feeding at night on sleeping prey. When the fly bites 
an animal infected with L. donovani, the pathogen is ingested along with the prey’s blood. At this point 
the protozoan is in the smaller of its two forms, called an amastigote; round, non-motile, and only three 
to seven micrometers in diameter. 
Taken into the stomach of the sand fly, the amastigotes quickly transform into L.donovani’s second 
form, called the promastigote. These forms are spindle-shaped, triple the size of the amastigote, and 
have single flagella that allows for motility. The promastigotes live extracellularly in the sand fly's 
alimentary canal for a few days, reproducing asexually, and then migrate to the salivary glands. This is 
their means of transmission back into a mammalian host, as the fly injects its saliva into prey when it 
bites, the promastigotes are introduced into the prey’s bloodstream along with the fly’s saliva. 
Once inside the new host, each promastigote attaches itself to a macrophage using its flagella. It is then 
taken alive into the cell through the macrophage’s own action of phagocytosis. Once inside, it 
transforms back into the smaller amastigote form. As an amastigote, L. donovani can only reproduce 
intracellular; the L. donovani lyses their host cell by sheer pressure of mass, the daughter cell protozoan 
then migrate through the bloodstream to find new macrophage hosts.  
After cutaneous inoculation of parasites, organisms spread throughout the mononuclear macrophage 
system to the spleen, liver, and bone marrow, the resulting clinical illness.( Killick-Kendrick R. 1990). 
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1.1.6-Incubation period 
The incubation periods for the different forms of leischmaniasis range from several days to months, in 
visceral infection, the incubation period typically ranges from weeks to months. However, incubation 
periods from days to years, and even decades, have been reported.  
The illness usually lasts about 1-20 weeks, in endemic areas of Western Sudan it lasts about 12-16 
weeks with and average of about 6 weeks. Relapse may occur as many as 10 years after first episode. 
1.2- Visceral leischmaniasis (VL) 
1.2.1- Magnitude of the Problem of VL. 
Leischmaniasis is prevalent through out the tropical and sub-tropical regions of Africa, Asia, the 
Mediterranean, Southern Europe (old world) and South and Central America (new world) (WHO: www 
site, 1997). 
It is estimated that approximately 12 million people are currently infected and a further 367 million are 
at risk of acquiring leischmaniasis in 88 countries, 72 of which are developing countries and 13 of them 
are among the least developed in the world. (WHO: www site, 1997).   
The annual incidence of visceral leischmaniasis is estimated to 500,000 cases with 90% of them 
occurring in Bangladesh, India, Nepal and Sudan, every year, up to 2 million new leischmaniasis 
infections occur, almost two thirds of these in the cutaneous form. In Southern Europe, V.L is frequent 
in HIV patients. In Spain, the majority of patients with V.L are now HIV-infected although there is 
much in favor of it; leischmaniasis is not an AIDS-defining illness (Pintado, et al. 2001).   
In the Mediterranean basin 1.5-9% of AIDS patients develop V.L and 25-70% of the adult VL cases are 
related to HIV infection (V. Pintado, et al. 2002).  
Both the new world and the old world forms of the disease display similar symptoms and are often 
complicated by secondary infections, and treatment of V.L is problematic (P . Olliaro, et al. 2004).  
1.2.2- Problem of VL. in Sudan 
VL is prevalent through out the tropical and sub-tropical regions, 90% of the annual incidence of 
visceral leischmaniasis are occurring in Bangladesh, India, Nepal and Sudan (Henry W. Murray. 2004).  
Leischmaniasis, in Sudan is also known as KA, spread by the sand fly vectors (Phlebotomus orientalis), 
and local agent is Leischmania donovani. 
Leischmaniasis, in the Sudan known in its worst [visceral] form as Kalazar, is a parasitic protozoan 
disease, that can affect internal organs. V.L. is most common in the Blue Nile, Upper Nile, Jonglei and 
Eastern region ( Gadaref state ), and the area north of Khartoum (figure1.2). Increasing activity has 
occurred in Eastern State, notably along the Rahad and Dinder rivers, Over 40,000 fatal cases were 
reported from the western Upper Nile during 1984-1991, and the death toll among the Nuer and Dinka 
Peoples was estimated at 200,000 during 1988 to 1995. From the late eighties to the mid-nineties a total 
of 100,000 succumbed to the sickness in that region alone. In the words of Jill Seaman, the doctor who 
led relief efforts in the Upper Nile for the French organization Medicins Sans Frontieres (MSF-
Holland), “Where else in the world could 50% of a population die without anyone knowing?”( El-
Hassan AM, et al. 1995; Elnaiem et al. 1997).  
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1.2.3- Problem of VL. in Gadaref State 
VL. is most common in the Eastern region (Gadaref state).  
Under the title (Kalazar in Sudan  ѧـ still a neglected disease?) in Khartoum, 9TH January 2005 – today, 
international humanitarian relief agency medicines Sans frontiers ( MSF ), presents special booklet 
about the disease kalaazar in Sudan.(The Booklet ''Kalaazar  still a  neglected  disease?"  is  based  on a 
collection of  stories  from patients and medical workers that achievements and challenges ahead) which 
stated that:  
“The  disease  is endemic  in  large parts  of  eastern  and southern Sudan, with a  clear  'belt'  running  
from Unity  State  in Southern  Sudan, through  Upper  Nile, Blue Nile  Sennar, and Gadaref, up to 
kassala in Eastern Sudan. Since 1997, MSFــHolland has managed a 400ــbed Kalaazar treatment facility 
in the Village of Um Kuraa (now widely know as Um el Kher), on the banks of the Rahad River in 
Gadaref State.  MSF will be leaving Gadaref in 2005 in order to focus resources in Areas of conflict, 
but remains committed to tackling Kalaazar, in Sudan and is working With the Ministry of Health and 
other actors to sustain our work. MSF ѧـHolland calls  on the  World  Health  Organization to  co  
 ѧـordinate  a  regional, Governmental  response  that explicitly tackles Kalazar as a neglected disease, in  
need of far wider awareness”  
13,000 VL cases were diagnosed in Gadaref State during the period March 1996 to December 2000, the 
only intervention program against VL was started in April 1999 by MSF-Holland, which distributed 
350,000 insecticide-treated bed nets to the inhabitants of VL endemic foci. (Thomson M, Connor S, 
2000; Elnaiem DA, et al. 1997). 
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Figure (1.2): Endemic areas of visceral and cutaneous leischmaniasis in 
Sudan. 
 
 
Study area 
\\\\\: Cutaneous leischmaniasis 
####: Visceral leischmaniasis 
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1.2.4- Symptoms of VL 
Various terms have been used to describe VL. including Dum-dum fever, Sikari disease, Burdwan 
fever, Shahib's disease and Tropical splenomegaly, however, the most commonly used term is Kalazar. 
The symptoms of VL. vary between individuals and according to geographical foci. However, some of 
the common symptoms include high undulating fever often with two or even three peaks in 24 hours 
and drenching sweats which can easily be misdiagnosed as malaria, chills, rigors, weight loss, fatigue, 
poor appetite, cough, burning feet, insomnia, abdominal pain, joint pain, anorexia, epistaxis and 
diarrhea. Clinical sings include splenomegaly, hepatomegaly and lymphadenopathy (Hashim et al, 
1994). 
When a human patient does develop VL, the most typical symptoms are fever and the enlargement of 
the spleen or splenomegaly, with enlargement of the liver. The blackening of the skin does not appear in 
most strains of the disease, and the other symptoms are very easy to mistake for those of malaria 
(Hashim et al, 1994). 
1.2.5- Complications of VL 
VL. can be complicated by serious secondary bacterial infections such as pneumonia, dysentery and 
pulmonary tuberculosis, which often contribute to the high fatality rate of visceral leischmaniatic 
patients. Other complications, though rare include hemolytic anemia, acute renal damage and severe 
mucosal hemorrhage (WHO expert committee report, 1991). 
Bacterial superinfection is one of the major complications leading to death in children with VL. 
Parasitic infestations of the gut are very common in pediatric VL. patients (Gagnaire, M.-H., et al. 2000; 
Gasser RA, et al.(1994).   
1.2.6- Post Kalazar Dermal Leischmaniasis (PKDL) 
Even with recovery, KA does not always leave its hosts unmarked. Some time after successful 
treatment generally a few months with African KA, or as much as several years with the Indian strain a 
secondary form of the disease may set in, called post kalazar dermal leischmaniasis (PKDL) This 
condition manifests first as small, measle-like skin lesions on the face, which gradually increase in size 
and spread over the body. Eventually the lesions may coalesce to form disfiguring, swollen structures 
resembling leprosy, and occasionally causing blindness if they spread to the eyes. This disease is not the 
same as CL which also causes skin lesions (Hashim et al, 1995; Ramesh et al, 1995; E.E. Zijlstra, et al. 
2000).  
1.2.7- Diagnosis Of VL. 
Preliminary diagnosis is based on the symptoms and clinical signs of VL such as splenomagaly, 
hepatomegally and high undulating fever. However these alone are not enough to differentiate VL from 
other similar conditions such as malaria, relapsing fever, liver abscess and trypanosomiasis. 
The differential diagnosis is wide, including hepatosplenic schistosomiasis, malarial hypersplenism, 
myeloproliferative diseases, typhoid Salmonella infections, miliary tuberculosis, brucellosis, 
histoplasmosis, subacute bacterial endocarditis, and infectious mononucleosis. When bone marrow 
macrophages are parasitized, anemia and leukopenia ensure. The thrombocytopenic patient may bleed 
from the gingivae, nose, or GI tract, and ecchymoses and petechiae may appear on the skin (Oren R, et 
al.1991).  
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While visceral VL. classically affects children, adults increasingly suffer infections in regions which are 
known to be endemic for HIV. Nowadays up to 70% of the patients with visceral leischmaniasis in 
southern Europe are HIV-infected adults. The diagnosis is known to be especially difficult to establish 
in this group of patients because of a frequently atypical clinical presentation, but even in non-HIV-
infected patients VL. often represents a diagnostic challenge particularly when the patient is living in a 
non-endemic region (V. Pintado, et al. 2002). 
Diagnostic difficulties arose from inexperience with this rare disease, long incubation period, travel 
history apparently unsuspicious for the contraction of what is considered a tropical disease and from 
clinical appearance and laboratory data mimicking hemophagocytic lymphohistiocytosis. Laboratory 
findings include; Anemia, leukopenia, thrombocytopenia, hyperglobulinemia, and hypoalbuminemia 
suggest visceral leischmaniasis when they are observed in a patient with fever, hepatosplenomegaly, 
and a history of exposure in endemic areas (Goldsmith, R.S. 1999). 
• Parasitological diagnosis  
Definitive diagnosis is made by the demonstration of amastigotes in tissue or by growing promastigotes 
in culture. Amastigotes are found in the macrophages of tissue sections and in touch preparations 
stained with Wright's and Giemsa stain.  
1- Spleen and liver biopsy  
Looking for parasites in the spleen and liver is one of the most accurate methods available to determine 
leischmanial infections; Ninety percent of the active cases show parasites in splenic and liver aspirates 
(Manson-Bahr, 1987).  
The smallest needle possible, preferably, 21-gauge (0.8 mm) should be used to minimize the risk of 
complications such as hemorrhage of the spleen (Williams, 1995).  
2- Marrow and lymph gland puncture 
Marrow obtained from sternal or iliac crest puncture is a much safer but a painful method. It is less 
likely to demonstrate parasites in direct stained films, however, on culture it can give positive results in 
up to 80% of the cases. Lymph gland puncture gives positive results in 60% of the cases, Juice is 
extracted from any enlarged lymph gland and subjected to both direct examination and culture to give 
the best chance of diagnosis (Williams, 1995). 
3- Blood buffy coat 
Finding the leischmania parasites in blood in sometimes possible in patients with Kalazar from Kenya 
and India. Blood in anticoagulant is centrifuged at 2000g for 10 min and the cells from the buffy coat 
removed and used to prepare smears and inoculate cultures. Amastigotes can be found in and around 
Macrophage cells. The volume used in culture inoculation is important, 1-3 drops on NNN or 
Schneider's medium has given successful results (Williams, 1995). 
• Serological diagnosis 
Serological diagnosis is based on the presence of specific humoral antibodies in cases of VL There are a 
range of serological methods available for the diagnosis of VL varying in accuracy and specificity. With 
on-going research newer better methods are continually becoming available (Sundar S, et al. 2006). 
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1.2.8- Treatment of VL 
The mortality of VL approaches 90% for untreated patients, whereas most patients will recover if 
treated, treatment for VL. is expensive and complicated by the fact that most current medications are 
given IV or IM. A range of treatment options exists in VL which include two pentavalent antimonials 
(meglumine antimoniate and sodium stibogluconate), four formulations of Amphotericin-B, 
aminosidine (paromomycin), pentamidine, and the new oral agent miltefosine, in addition to new drugs 
combination under research. For the clinician, the choice of treatment depends on several factors, such 
as the clinical features of the disease, as well as drug safety, efficacy, and cost (V. Vanlerberghe, et al. 
2007) 
1.2.8.1- Antileischmaniatic drugs 
1.2.8.1.1- Sodium stilbogluconate (SSG) 
SSG remains the most important antileishmanial drug in most parts of the world, it have been 
successfully used for treatment of KA since last six decades, since 1970s its conventional dosages have 
failed to achieve with 60 per cent unresponsiveness reported with WHO regimen in Bihar (India).  
SSG is the preferred treatment of VL however, tolerance of therapy may be reduced in patients in poor 
general condition, renal function impairment could be of concern as SSG salts are eliminated mainly in 
the urine. The literature contains no specific guidelines about reducing the dosage in patients with renal 
failure. The availability of cheaper generic SSG, subject to rigid quality controls, now makes it possible 
for the health authorities in KA endemic areas to provide treatment to many more patients in Africa (Ho 
M, Siongok TK, et al. 1982).  
In Ethiopian VL patients with normal renal function, SSG therapy at a daily dose of 20 mg/kg for up to 
30 days is safe and only rarely associated with clinically significant bradycardia which resolves after 
temporary cessation of therapy. Furthermore, in areas with limited facilities, monitoring the pulse rate 
during antimonial therapy (Berhe N, et al. 2001). 
1.2.8.1.2- Amphotericin- B (AmB) 
AmB appears far superior to SSG against VL which is injected infrequently and is easily tolerated, is 
virtually 100% effective for Indian visceral disease at a total dose of 15 mg/kg and is 90% effective at a 
dose of 5-10 mg/kg. AmB remains the drug of choice in most systemic mycoses and also as a second 
line treatment for Kala azar, However, its toxic effects often limit its use. Although the liposome 
delivery system has been tried for several drugs, only a few have been used in patients due to the slow 
development of necessary large-scale pharmaceutical procedures, it was found to be safe in patients 
who had developed serious unacceptable toxicity with conventional AmB. In renal transplant patients, 
AmB did not produce any nephrotoxicity ( Berman, J. & Dietz, R.1999). 
In the absence of any official drug policy for VL in Italy and in consideration of the large sample of 
patients surveyed, astudy, which may be the first observational investigation on VL. therapy at the 
national level from 1986 through 2001, results have shown a countrywide change in therapy over the 
period considered, a traditionally effective drug (meglumine antimoniate) has been almost fully 
replaced by a new compound, Liposomal AmB, in an epidemiologic context of disease reemergence.  
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Possible explanations for this change include, mild or severe adverse reactions (e.g., pancreatitis, 
cardiac abnormalities) are commonly seen in meglumine antimoniate–treated patients, especially in 
adults, treatment failures have increased in VL patients from Southern Europe and the highly cost-
effective treatment if compared with 21- to 28-day courses needed for meglumine antimoniate 
treatment.( Gradoni L, et al. 2003) 
Liposomal AmB is the first line treatment in developed countries, unfortunately, the high cost makes 
this treatment unaffordable for developing countries like Sudan (Thakur CP, et al. 2004). 
1.2.8.1.3- Paromomycin 
Paromomycin is an aminoglycoside antibiotic with anti-parasitic activity. Injectable paromomycin has 
been tested by one World Health as a treatment for VL. occurring on the Indian subcontinent. It can be 
used alone or along with the pentavalent antimonials for its synergistic action. Paromomycin has 
undergone extensive clinical trials in Indian KA patients. Being an aminoglycoside, acquired resistance 
is likely to occur when used as a monotherapy. To encounter the problem of treatment failure in KA and 
to reduce length of therapy, combination of at least two effective antileishmanial agents is a desirable 
option. In India SSG in standard dose has been combined with other antileishmanial agents including 
paromomycin without encouraging results (Sundar, S, et al. 2007).   
1.2.8.1.4- Miltefosine 
The research and development efforts for a cost-effective, safe and oral treatment for VL bore fruit 
when Professor Hansjorg Eibl, Max Planck Institute for Biophysical Chemistry, and Professor Clemens 
Unger in Gottingen, Germany, discovered a structurally simple molecule, miltefosine. Initially, 
miltefosine was tried for the management of cancer patients. The dose required for such treatment had 
pronounced side-effects, limiting its usefulness. Simultaneously, in vitro studies showed that it had 
striking activity against L. donovani and L. infantum.  
Preclinical studies using the same dosage as for anti-cancer treatment indicated that the drug had 
teratogenic effects, renal toxicity, and adverse effects on fertility in males. The dosage of the drug 
required for treatment of VL is, however, far less than that required for management of cancer, and 
consequently has reduced adverse reactions. The results of Phase III clinical trials of miltefosine in 
India have shown that this oral drug is very effective for treating VL in both adults and children, and 
has limited side-reactions, it produced cure rates approaching 100% (Berman J, 2005). 
It has negligible side effects, does not require refrigeration for storage, and has been used successfully 
to treat cases resistant to conventional antimony therapy.  
Since the drug can be administered orally, it has the potential to be used as a simple and affordable 
public health tool to treat patients effectively at the community level and even during epidemics. 
The availability of an oral anti-leishmaniasis drug may revolutionize the treatment and control of KA 
and alleviate the sufferings of the millions of adults and children in affected countries (Desjeux P. 
(2001; Berman J, 2005). 
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1.2.8.2- Drug resistance 
Throughout the world, SSG have been the mainstay of antileishmanial therapy for more than 50 years, 
and has been highly effective in the treatment of Indian VL at a low dose (10 mg/kg) for short durations 
(6–10 days), But in the early 1980s reports of its ineffectiveness emerged, and the dose of SSG was 
eventually raised to 20 mg/kg for 30–40 days.  
This regimen cures most patients with VL except in India, where the proportion of patients 
unresponsive to SSG has steadily increased. In hyperendemic districts of north Bilhar, 50–65% patients 
fail treatment with SSG (Shyam Sundar, 2002).   
VL caused by Leishmania infantum remains difficult to treat in patients with AIDS because of parasite 
resistance and high rates of relapse.( Jean-Pierre Gangneux, et al. 1996).  
 
Important reasons are rampant use of subtherapeutic doses, incomplete duration of treatment and 
substandard drugs. In vitro experiments have established emergence of SSG resistant strains of L. 
donovani, as isolates from unresponsive patients require 3–5 times more SSG to reach similarly 
effectiveness against the parasite as in SSG responders. Anthroponotic transmission in India has been 
an important factor in rapid increase in the SSG refractoriness, pentamidine was the first drug to be used 
and cured 99% of these refractory patients, but over time even with double the amount of initial doses, 
it cures only 69–78% patients now and its use has largely been abandoned in India. Despite several 
disadvantages, AmB is the only drug available for use in these areas (Thakur CP, et al. 2004; M. 
Ouellette, et al. 2004).    
1.2.8.3- Combination treatment 
Combination therapy has been pursued for a number of reasons. First, the gradual increase in resistance 
to SSG monotherapy. Combination therapy could be a means to prevent/delay drug resistance, as has 
been successfully employed for malaria, tuberculosis and HIV. Second, combination therapy could 
improve treatment efficacy for complicated cases, like HIV-coinfection. Third, combining two drugs 
could allow reducing treatment duration and/or total drug doses, resulting in lesser toxicity, higher 
compliance, less burden on the health system, and, by reducing overall costs, a more cost-effective 
option. The main combinations currently under consideration in India are L-AmB + Miltifosine, L-
AmB + Paramomycin, Miltifosine + PM. L-AmB + SSG and SSG + Paramomycin combinations are 
being studied in Africa. The first Phase 2 results from India revealed several short combination 
therapies of low dose L-AmB and Miltifosine (7-14 days) that merit further exploration.(Johan van 
Griensven, Combination therapy for visceral leishmaniasis: why, what and where?) 
Standard treatments for VL (antimonials, AmB and pentamidine) pose several problems; failure of 
antimonials and severe toxicity is particularly troublesome in patients with renal insufficiency, 
areported case of VL and renal insufficiency is successfully treated with fLuconazole (FL) and 
allopurinol for 4 months (Colakoglu M, et al. 2006) 
Whereas certain oral antifungal azoles are well documented to have activity against leishmania, data on 
the efficacy of FL for leishmaniasis are limited. a controlled trial is conducted in Saudi Arabia of FL for 
the treatment of CL caused by Leishmania major, this randomized, double-blind, placebo-controlled 
trial assessed the efficacy of oral fluconazole, in a dose of 200 mg daily for six weeks, in the treatment 
of parasitologically confirmed CL. The primary outcome measure was the time to the complete healing 
of all lesions. A six-week course of oral FL is a safe and useful treatment for CL caused by L. major.( N 
Engl J Med.  2002 ) 
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For CL, two new oral drugs, FL and Miltefosine, provide wider options to the clinician.(Berman J. 
2003; Alrajhi AA, et al. (2002).     
The combination of interferon gamma and pentavalent antimony is effective in treating seriously ill 
patients with refractory or previously untreated VL (R. Badaro, et al. 1990) 
Paramomycin 12 or 18 mg/kg daily plus a standard dose of SSG for 21 days was statistically more 
effective than SSG in producing a final cure for patients with VL in Bihar, India.(C.P. Thakur, et al. 
2000). 
In a murine model of Leishmania infantum VL, metronidazole, ketoconazole, FL, itraconazole, and 
terbinafine were less effective than antimonial agents in reducing hepatic parasite load. Ketoconazole 
potentiated the effect of meglumine antimoniate reference therapy through its marked activity against 
spleen infection, however, their use in the treatment of CL and VL caused by different Leishmania 
species has produced conflicting results (Jean-Pierre Gangneux, et al.1999)  
Nicolas Mbongo and co-workers. 1998, recently showed that resistance of L. donovani promastigotes to 
AmB involves the substitution of another sterol for ergosterol in the cell membrane, change in 
membrane fluidity, and a weak affinity of AmB for such modified membranes and they, L. donovani 
promastigotes  were highly susceptible to ketoconazole. 
Although it is now agreed that the therapeutic response varies with the parasite species, few data are 
available on L. infantum sensitivity. Before these compounds are used again for the treatment of VL in 
HIV patients, it seems judicious to evaluate their specific anti-L. infantum activity in order to better 
define the rationale for their prescription (Murray, H. W. 2001). 
FL when used with SSG significantly increase the blood concentration and prolong the elimination half-
life of SSG.(L. Alnaim, et al 2007) 
 
1.2.8.3.1- Fluconazole (FL) 
FL is a synthetic antimycotic drug of the triazole class of compounds, it is used orally and intravenously 
to treat yeast and other fungal infections. 
FL inhibits, much like the imidazole-antimycotics, the fungal P450-enzyme. The consequences are that 
Lanosterol can no longer be converted to Ergosterol which is an essential part of the fungal membrane 
and its deficit alters the permeability of the membrane and disrupts fungal growth. It acts fungistatic or 
fungizide depending on the susceptibility of the strain and the dose regime used. FL is theoretically 
capable of inhibiting demethylases in the human body, but this effect is not seen with therapeutic doses. 
Animal models (infection studies) showed that FL is active against infections with strains of Candida, 
Cryptococcus, Aspergillus, Blastomyces, Coccidioides and Histoplasma. In vitro test systems are still 
inreliable. 
Following oral dosing, FL is almost completely absorbed within two hours. The high bioavailability of 
over 90% is not significantly reduced by concomitant intake of meals and co-medication with H2-
antagonists (e.g. cimetidine, ranitidine).  
The half-life of FL is approximately 30 hours and is increased in patients with impaired renal function. 
FL is renally eliminated and primarily (80%) excreted in the urine as unchanged drug. 
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Male rats treated with 5 mg and 10 mg/kg weight respectively showed a higher incidence of 
hepatocelluar adenomas than expected. No data exists on human carcinogenity. 
FL. is used for the treatment of:: 
o Infections with Candida in mouth and esophagus.  
o Recurrent vaginal infections, if local therapy is not sufficient.  
o Prophylaxis of infections with Candida in tumor patients receiving chemo- or radiotherapy.  
o Treatment of deep or recurrent fungal infection of the skin (dermatomycosis), if local treatment 
was not successful. The efficacy of FL in the treatment of onchomycosis (fungal infection of the 
nails) has not been demonstrated.  
o Sepsis due to emergence of Candida in the blood (candidaemia).  
o Meningitis and prophylaxis of meningitis caused by cryptococcus in AIDS-Patients. In a 
subgroup of patients FL. acts more slowly than AmB alone or in combination with flucytosine. 
Nonetheless, response and curation rates were not significantly different.  
o Treatment of blastomycosis, histoplasmosis, coccidioidomycosis, sporotrichosis, and 
aspergillosis. Sometimes AmB is the preferred agent.  
o Off-label uses include Infections with cryptococcus on other locations of the body (e.g. on the 
skin or pulmonary).  
o Prophylaxis of fungal infections in patients with AIDS, posttransplant-patients, or otherwise 
immunecompromised patients.  
Hypersensitivity to FL is an absolute known contraindication.  
FL. may infrequently cause severe or lethal hepatotoxicity.  
FL. may cause rare cases of prolongation of the QT interval, leading to serious arrhythmias. Risk 
factors are preexisting prolonged QT interval, electrolyte imbalances including hypokalemia, low serum 
level of magnesium and hypocalemia.  
The use in newborns, children and adolescents is possible. Newborns up to 4 weeks excrete FL very 
slowly, while the half-life in older children and adolescents is reduced to 20 hours. 
High concentrations in the milk of breastfeeding mothers have been measured.  
Side-effects of FL are gastro-intestinal tract: Nausea, dyspepsia, abnormal taste, abdominal pain, 
vomiting, diarrhea, and flatulence were reported in 5.3% of patients. In female patients receiving a high 
single dose treatment for vaginal infections, the incidence of these side-effects may be higher.  
Skin rash, diffuse reaction with eosinophilia, and pruritus were encountered in up to 5%. Also alopecia 
and exfoliative skin reactions (including Stevens-Johnson-Syndrome and Lyell's-Syndrome) were seen.  
Liver, kidney and hematology in Some patients, particular those with AIDS or malignancies, developed 
increased liver enzymes, bilirubin, serum creatinine, eosinophilia, anemia, and leukopenia including 
agranulocytosis as well as thrombopenia.  
Dose is According to individual scheme depending on disease, weight of the patient and renal function. 
Therapy is either orally or per I.V.-infusion. Duration of treatment or prophylactic treatment is also 
strictly individual.  
Warfarin and FL. are frequently encountered drugs in the emergency department and thus any 
interaction between these drugs is of considerable importance.(Eur J Emerg Med.  2002). 
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Use with oral antidiabetic agents has increased the plasma concentration of these sulfonylurea agents, 
leading to hypoglycemia. 
At FL doses of 400 mg per day or greater, concurrent use with terfenadine is contraindicated and may 
increase the risk of cardiac arrhythmias, including torsades de pointes. 
Findings in a clinical study indicate that the interaction between FL. and disopyramide has a marked 
influence on the heart rate in chick embryos. (Biol Pharm Bull.  2005 ) 
The most frequent interactions with potential moderate to major severity were co-administration of FL. 
with prednisone (25.3%), midazolam (17.5%), warfarin (14.7%), methylprednisolone (14.1%), 
cyclosporine (10.7%) and nifedipine (10.1%).  
Potential FL drug interactions were very frequent among hospitalized patients on systemic azoles 
antifungal therapy, but they had few apparent clinical consequences (Pharmacy information about 
(FL.1996-2001. MedicineNet, Inc.) 
1.2.8.3.2- FL Vs  ketoconazole  
FL appears to be superior to ketoconazole for treating AIDS-associated candida esophagitis, with 
significantly greater rates of endoscopic and clinical cure... 
Uunlike FL ketoconazole has been shown to suppress corticosteroid secretion and lower serum 
testosterone concentrations. 
Ketoconazole Drug interactions include, Alcohol and hepatotoxic medications may increase the risk of 
hepatotoxicity, different drugs like antacids, anticholinergics/antispasmodics, histamine H 2-receptor 
antagonists, omeprazole, or sucralfate will increase the pH of the stomach and decrease the absorption 
of ketoconazole, Ketoconazole may increase digoxin concentrations leading to digoxin toxicity, 
Ketoconazole may increase plasma concentrations of indinavir and the use of ketoconazole with 
midazolam or triazolam may potentate the hypnotic and sedative effects of these benzodiazepines. 
Also use of ketoconazole with astemizole, cisapride, or terfenadine is contraindicated and may increase 
the risk of cardiac arrhythmias, including torsades de pointes. 
ketoconazole show an increased risk of hepatotoxicity and of side effects due to inhibition of 
testosterone and corticosteroid synthesis, such as menstrual irregularities, oligospermia, azoospermia, 
impotence, and decreased male libido (Bodey GP. 1992) 
Pharmacology and pharmacokinetics differences between FL and ketoconazole are shown in tables 
(1.1) and (1.2). (De Wit S, Goossens H, Weerts D, et al. 1989)  
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Table (1.1): Pharmacology and Pharmacokinetics properties of FL and ketoconazole - 1 
 
Drug Route of 
administration 
Bioavailability 
(%) 
Vol D CSF/Serum 
concentrations 
(%) 
Protein 
binding 
(%) 
Metabolism
Fluconazole  IV, PO   90 (fasting)   0.7-1 L/kg 
54-85 
(patients with 
meningitis)  
11  Hepatic †  
Ketoconazole 
  PO  75 (with food) 
0.36 
L/kg  < 10  99  Hepatic  
• IV = intravenous; PO = oral; Vol D = apparent volume of distribution; CSF = cerebrospinal 
fluid; L/kg = liters per kilogram. 
† FL is primarily excreted by the kidneys; however, a small amount of the drug undergoes 
hepatic metabolization. 
 
 
 
Table (1.2): Pharmacology and Pharmacokinetics properties of FL and ketoconazole - 2 
 
 Half-life (hr)  Peak serum 
concentration 
after dose 
  
Drug Normal 
renal 
function 
Impaired renal 
function 
Time to peak 
serum 
concentration 
(hr) 
mcg/mL Dose Renal 
excretion 
(% 
unchanged)
Biliary 
excretion 
Fluconazole  
30 (adults)
14-20 
(children)  
98-125   1-2  4.5-8  100 mg  > 80  Yes; small amount  
Ketoconazole 
  8  
  
1-4  3.5  
200 mg 
(with 
food)   
2-4  
Yes; primary 
route of 
elimination 
 
 
 
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 31 -
1.3. Rationale of the Study 
Recently much attention was directed to the problem of VL as a consequence of emergence of   many 
catastrophic complications in Gadaref State. 
Furthermore, several relapse cases were reported, and the number according to many sources is still 
increasing.  
Development of newer antileischmanial drugs is rare. Lipid associated AmB has an excellent safety and 
efficacy profile, but remains out of reach for most patients because of its high cost. Antimony resistant 
strains of L. donovani were wide spread over different geographical areas. Use of combination therapy 
is one of therapeutic options available to prevent further development of resistance against the limited 
therapeutic options available. 
Therefore there is a need for alternatives to antimonial agents and AmB, especially for drugs that are 
effective by the oral route.  
Metronidazole and sterol biosynthesis inhibitors (ketoconazole, FL, itraconazole, and terbinafine) are 
well-tolerated drugs that are potentially active against Leischmania when given by mouth.  
This hospital based study was designed to address this problem by attempting to introduce amore 
efficient combination therapy (SSG + FL.). 
Ethical clearance certificate was obtained from the National Health Research Ethics Review Committee 
- National Ministry of Health which approved this clinical study to be carried out in Sudan - Gadaref 
State. 
 
1.3.1. General Objectives   
a. To determine the alternative approach of using combination therapy against VL. rather 
than monotherapy with SSG. 
b. To investigate efficiency and safety of the suggested combination therapy SSG and FL. 
to monotherapy SSG in the treatment of VL.  
 
1.3.2. Specific Objectives  
           (1) To minimize the duration of treatment of VL. by SSG monotherapy and decrease 
hospitalization of VL. Patients. 
(2) To decrease resistance to SSG monotherapy. 
(3) To decrease the overall cost of treatment of VL. by SSG monotherapy. 
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CHAPTER TWO 
 
Methodology 
2.1- methods 
 
a- Study area 
Gadaref teaching hospital in Gadaref State was chosen as the study area due to high numbers of VL. 
patients admitted to this hospital. The patients selected were admitted in this hospital for one month 
under doctor supervision. Many meetings were held with the consultants and other clinicians in 
department of medicine to discuss the research work. 
? Gadaref State description 
Gadaref is a big town, capital of Gadaref State,  located at middle of the eastern region of Sudan, about 
400 Km south-east Khartoum, Gadaref State has a total population of 1,137,642 people according to the 
most recent estimate, (Statistics Department, Gadaref State, Sudan)  (National Consensus Body, 2004). 
The human population of Gadaref State belongs to many ethnic groups, most of whom have a recent 
history of settlement in the region; the climate of the region is tropical continental, with an estimated 
annual rainfall of 400–1,400 mm. The year is sharply divided between the rainy season, June–October, 
and the dry season, November–May. The natural vegetation of the area is dry savanna woodland. The 
main indigenous trees in the region are B. aegyptiaca (known locally as "hig-leeg"), A. seyal ("Taleh"), 
Acacia Senegal ("Hashab"), Acacia mellifera ("Kiter"), Combretum spp., Calotropis procera ("Usher"). 
Some fruit orchards are found. Dura (Sorghum pupura), sesame (Sesamum orientale), Dokhon 
(Pennisetum typhodium), and groundnuts (Arachis hypogaea) are grown as cash crops over extensive 
areas. (Statistics Department, Gadaref State, Sudan)   
? Gadaref State hospitals 
Gadaref  town comprises many working hospitals:  Gadaref teaching Hospital (medicine, surgery and 
pediatric), Obstetrics  and Gynecology Hospital,  Ophthalmology Hospital, Military Hospital, Military 
Private Hospital, Dental Hospital, and Police Hospital, other working hospitals that scattered all over 
the state include; Taparak Allah Hospital, Kassap hospital, Hillat hakims hospital, Pazoora hospital, 
Umelkheer hospital, Dooka hospital, Alhawata hospital, Pasunda hospital, Alshwak hospital, Alfao 
hospital, Galaelnahal hospital and Almafaza hospital (Reports of the Ministry of Health, Gadaref State, 
Sudan). 
b- Selection of patients 
A total number of 44 patients were randomly selected in the study area from May 2005 to October 
2007. Diagnosis of VL was done by clinical and laboratory (parasitological) examination. 
Written patients consent was obtained from participants by signing the information sheet and consent 
form. 
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c- Inclusion and Exclusion criteria 
 
Inclusion criteria for the VL. patient to enter the study were 
a) Clinically and parasitological diagnosed VL. patients.  
b) Age of patients over 16 years old.  
Exclusion criteria include: 
a) Relapsed VL patients resistant to SSG,  
b) Patients infected with AIDS,  
c) Severe vomiting that interfere with oral treatment.  
d) History of hepatotoxicity. 
 
2.2- Laboratory procedures 
 
a. Gland puncture test 
Juice is extracted from any enlarged lymph gland and VL parasites was demonstrated in direct stained 
film using Giem,s Stain and the slide prepared was subjected to examination under a microscope using 
paraffin oil. 
b. Bone marrow aspiration test 
Marrow smear is obtained from sternal or iliac crest puncture, a direct stained film is prepared using 
Giem, s Stain and the slide prepared was tested for VL parasites under a microscope using paraffin oil. 
c. Spleen puncture test 
The smallest needle possible, preferably, 21-gauge (0.8 mm) is used to obtain splenic aspirate which is 
subjected to examination under a microscope using paraffin oil after a direct stained film was prepared 
by Giem,s Stain. 
   
2.3- Biochemical and hematological procedures 
 
Biochemical and hematological tests including, Liver function test (billirubine, protein and enzymes), 
Blood urea, hob%, TWBC. These tests were done on admission and repeated on day 15 and day 30 of 
treatment. some of these tests were performed more frequently as necessary during the management of 
ill patients. 
These tests were done using the different methods according to the method prescribed, then compared 
with the normal values according to the method used (Table 2.1). 
 
2.4- Clinical procedures 
The patients were examined by a medical doctor on admission for the following: complaints (headache, 
GIT symptoms, urinary tract (UT) symptoms, respiratory tract (RT) symptoms and epistaxis.); history 
(drug history, disease history, liver history, renal history); general examination (fever, pale, jaundice); 
abdominal examination (spleenomegaly; hepatomegaly); cardiovascular examination (arrhythmia). 
Patients were examined on admission and evaluated by repeating the same examinations on day 7, 14, 
21 and 30 of treatment. 
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Chest x-ray and electrocardiograph (ECG) were done on admission and repeated on day 15 and 30 of 
treatment. 
The patients were weighed on admission and at day 7, 14, 21 and 30 of treatment. 
 
2.5- Management of patients 
The general treatment measures for visceral leischmaniasis were applied to the patients depending on 
their initial signs and symptoms on admission. Medication and nursing care was provided to all patients. 
All patients were subjected to daily monitoring and follow up. 
 
2.6- Therapeutic regimens used 
Group one (22 patients) 
SSG 20 mg/kg intravenous injection daily for 30 days 
Group two (22 patients) 
SSG 20 mg/kg intravenous injection daily for 30 days plus FL oral tablets 150 mg (one tablet) daily for 
30 days (table 2-2) 
  
2.7- Evaluation criteria for the treatment efficacy and safety 
 
a- Efficacy assessment 
efficacy was assessed using parameters including; parasite clearance time, fever clearance time, clinical 
cure rate, mortality rate, improvement of clinical signs and symptoms (weight gain, spleen size 
reduction, liver size reduction, recovery and general patient condition), improvement of impaired 
biochemical and hematological parameters (increase in hemoglobin percent and white blood cell count). 
b- Safety assessment 
Side effects were defined as signs and symptoms that first occurred or became more severe after 
treatment started. Any new events occurred during treatment were also considered as side effects. 
Biochemical and hematological parameters were also evaluated pre- and post- the initiation of therapy 
to detect any changes that should be regarded as side effects of the therapy. 
 
2.8- Data analysis 
The demographic, clinical and laboratory data for each patient was entered in a form then entered in 
SPSS for windows version 12 for the performance of the descriptive and comparative statistical 
analysis. T- Test, qui square and cross tabulation were used for the comparison between the two groups 
that used different therapy.  
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Table 2-1: Methods of biochemical and hematological test 
 
Test Method Normal values according to 
the method used 
Hemoglobin Sahli method 12.0 – 16.0 gm/dl (82.2% - 
109.6%) 
TWBC Dilution white blood cell count 
method 
4000 - 11000/cmm 
Blood urea Berthelot method 10- 50mg/dl 
Liver function test (bilirubin, 
albumin, protein)  
Colorimetric method T. billirubine    up to 1.1 mg/dl 
D. bilirubin      up to 0.3 mg/dl 
Protein             6.0 – 8.0 gm/dl 
Albumen          3.5 – 5.3 gm/dl 
 
 
 
 
Table (2-2): Drugs used in the study of the efficacy and safety of sodium 
stilbogluconate alone and in combination with fluconazole in the treatment of 
visceral leischmaniasis 
 
Drug Source 
Sodium Stilbogluconate BP IM, IV 
Injection equivalent to100 mg/ml 
pentavalent antimony. Bottle of 30 
ml.  
 
 Albert David Limited – India 
(IDA foundation - Netherland- 
Amistardam.) 
Donation -UNICEF- WHO 
Fluconazole tablets 150 mg 
(Candivast) 
Advanced Pharmaceutical industries 
Co. ltd.- Jordan 
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CHAPTER THREE 
 
RESULT 
 
3.1- Visceral leischmaniasis in Gadaref State  
13,000 VL cases were diagnosed in Gadaref State during the period March 1996–December 2000, and 
the total number of new cases, relapse and mortality in the year 2005, 2006, 2007 and 2008 is shown in 
table (3-1A, B, C). (Reports of the Ministry of Health, Gadaref State, Sudan) 
The only intervention programme against VL was started in April 1999 by Médecins Sans Frontières 
Holland (MSF-Holland), which distributed 350,000 insecticide-treated bed nets to the inhabitants of VL 
endemic foci. (Thomson M, Connor S, 2000) 
Total number of VL. patients, mortality and relapse in Gadaref Teaching Hospital alone for the years 
2005, 2006, 2007 and 2008 are shown in tables (3-2A, B, C). (Reports of the Ministry of Health, 
Gadaref State, Sudan) 
In Gadaref state total number of VL patients, number of relapse cases, mortality, and PKDL in 2007 
increased by different rates from 2006. (Table 3-3A). (Reports of the Ministry of Health, Gadaref State, 
Sudan) 
Also in 2008 number of VL patients, relapse cases, mortality, and PKDL increased by different rates 
from 2007. (Table 3-3B). (Reports of the Ministry of Health, Gadaref State, Sudan) 
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Total number of VL patients, relapse and mortality in the year 2005, 2006, 2007 and 
2008 in Gadaref State 
 
2005
4138
2006
2792
2007
2751
2008
3277
Total 4138279227513277
Year 2005200620072008
1234
Table (3-1A) No. of VL patients in 
Gadaref State in 2005, 2006, 2007 
and 2008 
Table (3-1B) VL relapse in Gadaref State in 
2005, 2006, 2007 and 2008 
2005
121
2006
74
2007
88
2008
129
Relapse 1217488129
Year 2005200620072008
1234
Table (3-1C) VL mortality in 
Gadaref State in 2005, 2006, 2007 
and 2008 
2005
186
2006
109
2007
117
2008
89
No.of death 18610911789
Year 2005200620072008
1234
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Total number of VL patients, relapse and mortality in the year 2005, 2006, 2007 and 
2008 in Gadaref Teaching Hospital 
 
 
 
 
 
Table (3-2A) No. of VL patients in 
Gadaref teaching hospital in 2005, 
2006 and 2007 and 2008 
2005
322
2006
478
2007
408
2008
273
Total no.of patient 322478408273
year 2005200620072008
1234
Table (3-2C[) VL mortality in 
Gadaref teaching hospital in 2005, 
2006 and 2007 and 2008 
2005
23
2006
32
2007
35
2008
31
No.of death 23323531
year 2005200620072008
1234
Table (3-2B) VL relapse, in Gadaref 
teaching hospital in 2005, 2006 and 2007 
and 2008 
2005
17
2006
37
2007
7
2008
5
Relapse cases 173775
year 2005200620072008
1234
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Table (3-3A) Rate of change in new infections, relapse, PKDL number of death and total 
number of kA patients between the year 2006 and 2007 in Gadaref state 
Variant Year 2006 Year 2007 Rate of change 
New infection 2642 2619 Decreased by 0.87%
Relapsed cases 74 88 Increased by 18.9%
PKDL cases 76 44 Decreased by 42.1%
Total no. of patients 2792 2751 Decreased by 1.46% 
No. of death 109 119 Increased by 9.17%
 
PKDL = Post kalazar dermal leischmaniasis 
 
in Gadaref State 2008 ,2007 changes between the year Rate of VL) B3-3(Table   
  
Variant  Year 2007 Year 2008 Rate of change 
New infection 2619 3034 
increased by 13 % 
Relapsed cases 88 129 
Increased by 32 % 
PKDL cases 44 114 increased by 61 % 
Total no. of 
patients 2751 3277 
increased by 16 % 
No. of death 119 89 decreased by 24 % 
 
PKDL = Post kalazar dermal leischmaniasis 
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3.2- Age and gender 
Total number of patients participated in this hospital based study were 44 patients, all of them were 
males. 
The age of the patients range from 16 to 75 years of age, most of  them are in the productive age from 
16 to 40 years, 37 % were from 16 to 24 years of age and nearly half of them(48 %) were 25 to 40 years 
of age (table 3-4). 
3.3- Drugs used for treatment 
22 patients (50%) of the total number of patients received SSG only ( dose of 20 mg /kg for 30 days ) 
for the treatment of VL, and the other 22 patients (50%) received  a combination therapy of SSG and FL 
( dose of 20 mg /kg  I.V for 30 days and 150 mg oral daily dose for 30 days respectively) (table 3-5). 
3.4- Complaints and history 
All VL patients receiving different therapy came with fever only or fever with other symptoms, and the 
majority of the two groups had no renal, liver or drug history (table 3-6).  
3.5- General, abdominal and cardiovascular examination 
Most of VL Patients of the two groups on abdominal examination showed spleenomegaly or 
spleenomegaly with hepatomegaly. 
On general examination, nearly 2/3 of the VL patients of the two groups were febrile and 1/3 was 
febrile and pale. 
None of VL patients were arrhythmic on cardiovascular examination (table 3-7). 
3.6- Fever state throughout treatment 
Fever was relieved within one week for 86.4% of VL patients receiving SSG and also for those 
receiving the combination therapy of sod. SSG and FL, and it was relieved within two weeks for the 
remaining percentage of the two groups (13.6%) (Table 3-8). 
3.7- Spleen size before and after treatment 
Before starting treatment very low percentage of the two groups showed normal spleen size without 
enlargement, and the other high percentage showed different spleen size enlargement ranged from 1 cm 
to 20 cm, but After treatment it was opposite, high percentage of the two groups showed normal spleen 
size and the low percentage showed different rates of spleen size enlargement (table 3-9). 
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Table (3-4) Age and gender of total number of VL patients participated in the study of 
the efficacy and safety of SSG alone and in combination with FL in the treatment of VL 
Age in years Frequency Percent Gender Frequency Percent 
16-24 17 37.0 % Male 44 100% 
25-40 20 47.8 % Female 0 0.0 % 
41-50 5 10.9 %    
51-60 1 2.2 %    
71-75 1 2.2 %    
Total 44 100.0 % Total 44 100.0 % 
 
Table (3-5) Drugs used for the treatment of VL patients participated in the study of the 
efficacy and safety of sodium stilbogluconate alone and in combination with fluconazole 
in the treatment of visceral leischmaniasis 
 
 
 
 
 
 
 
 
 
 
Drugs used Frequency Percent 
Sodium stilbogluconate 22 50 % 
Sodium stilb.+ Fluconazole 22 50 % 
Total 44 100.0 % 
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Table (3-6) Complaints and history for VL patients receiving different drug therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drugs used for treatment Group Variable 
SSG SSG+FL 
Fever only 
 
10 
45.5% 
12 
54.5% 
Fever with RT, GIT or 
UT symptoms 
8 
 
36.4% 
5 
 
22.7% 
Fever with headache 
and/or epistaxis 
4 
 
18.2% 
3 
 
13.6% 
patient 
complaints 
 
Fever + other symptoms 0 
0 
2 
9.1% 
liver history 
 
0 
0 
0 
0 
Drugs history 
 
0 
0 
1 
4.5% 
patient history 
No renal, liver or drug 
history 
22 
100% 
21 
95.5% 
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Table (3-7) General, abdominal and cardiovascular examination for the VL patients 
receiving different drug therapy 
Drugs used for treatment Group Variable 
SSG SSG+FL 
Febrile 
 
15 
68.2% 
14 
63.6% 
Febrile & pale 
 
6 
27.3% 
8 
36.4% 
General 
examination 
Febrile, pale & jaundice 
 
1 
4.5% 
 
 
Hepatomegaly 
 
1 
4.5% 
1 
4.5% 
Spleenomegaly 
 
9 
40.9% 
7 
31.8% 
Hepatomegaly & 
spleenomegaly 
8 
36.4% 
11 
50% 
Abdominal 
examination 
 
 
 
 
 
 
No hepatomegaly or 
spleenomegaly 
4 
18.2% 
3 
13.6% 
Cardiovascular 
examination 
No arrhythmia 
 
22 
100.0% 
22 
100.0% 
 
Table (3-8) Fever state throughout treatment for VL patients receiving different drug 
therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
Fever relieved 
within one week 
 
19 
86.4% 
19 
86.4% 
Fever throughout 
treatment 
 
 
 
Fever releived 
within tow weeks 
 
3 
13.6% 
3 
13.6% 
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Table (3-9) Spleen size at day zero before starting treatment and day 30 after completion 
of treatment for VL patients receiving different drug therapy 
Drugs used for treatment 
 
Variable Group 
SSG SSG+FL 
Not enlarged 
 
4 
18.2% 
4 
18.2% 
1-2 cm 
 
5 
22.7% 
3 
13.6% 
3-5 cm 
 
6 
27.3% 
2 
9.1% 
6-8 cm 
 
4 
18.2% 
8 
37.5% 
9-10 cm 
 
2 
9.1% 
1 
4.5% 
10-15 cm 
 
1 
4.5% 
3 
13.6% 
Spleen size at day zero 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16-20 cm 0  
1 
4.5% 
Not enlarged 
 
17 
77.3% 
13 
59.2% 
1-2 cm 
 
2 
9.1% 
2 
9.1% 
3-5 cm 
 
1 
4.5% 
2 
9.1% 
6-8 cm 
 
 
0 
3 
13.6% 
16-20 cm 0  
1 
4.5% 
Spleen size at day 30 
 
 
 
 
 
 
 
 
 
 
Not examined, the 
patient died 
2 
9.1 
1 
4.5 
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3.8- TWBC before and after treatment 
TWBC before starting treatment was very low, below the normal range, nearly for the total VL patients 
of the two groups of treatment. TWBC was slightly increased after treatment for the tow groups of 
treatment (table 3-10). 
3.9- Lymph node state throughout treatment 
lymph node enlargement was not subsided after treatment completion for moderate percentages of the 
total V.L. patients of the tow groups (31.8% of VL. patients receiving SSG and 54.5% receiving the 
combination therapy of SSG And FL.), and lymph node enlargement of the remaining percentage was 
subsided within 1,2,3,4 weeks from starting treatment or there was no lymph node enlargement from the 
start (table 3-11). 
3.10- Weight of VL patients before and after treatment 
Generally VL. patients of the tow groups receiving different therapy gain weight after completing 
treatment (table 3-12). 
3.11- Hb % before and after treatment 
Hemoglobin % increased in variable way after treatment for the V.L. patients of the tow groups 
receiving different therapy (table 3-13). 
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Table (3-10) TWBC before starting treatment and after completing treatment for VL 
patients receiving different drug therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
<2500/cmm 
 
15 
68.2% 
12 
54.5% 
2500-3500 
 
4 
18.2% 
6 
27.3% 
3501-4500 
 
3 
13.6% 
2 
9.1% 
4501-5500 
 
 
0 
1 
4.5% 
Total white blood 
cells 
Before starting 
treatment 
 
 
 
 
 
 
 
 
 6501-7500 
 
 
0 
1 
4.5% 
<2500 / cm 
 
5 
22.7% 
7 
31.8% 
2501 / cm - 3500 / cm 
 
7 
31.8% 
3 
13.6% 
3501 / cm - 4500 / cm 
 
5 
22.7% 
5 
22.7% 
4501 / cm - 5500 / cm 
 
1 
4.5% 
 
1 
4.5% 
5501 / cm - 6500 / cm 
 
1 
4.5% 
3 
13.6% 
6501 / cm - 7500 / cm 
 
1 
4.5% 
2 
9.1% 
Total white blood 
cells 
After completing  
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not investigated, the patient died 
 
2 
9.1% 
1 
4.5% 
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Table (3-11) Lymph node state through treatment for VL patients receiving different 
drug therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
2 3 No lymph node 
enlargement 
 9.1% 13.6% 
4 3 
 
Subsided after one week 
 
18.2% 13.6% 
3 
  
Subsided after 2 weeks 
 
13.6%  
2 1 Subsided after 3 weeks 
 9.1% 4.5% 
2 2 Subsided after 4 weeks 
 9.1% 9.1% 
7 12 Not subsided 
 31.8% 54.5% 
2 1 
lymph node 
state through 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 The patient died 
 9.1% 4.5% 
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Table (3-12) Weight in kg before starting treatment and after completing treatment for 
VL patients receiving different drug therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
4 0 35-40 kg 
 18.2% 0 
5 2 41-45 
 22.7% 9.1% 
3 6 46-50 
 13.6% 27.3% 
5 5 51-55 
 22.7% 22.7% 
2 6 56-60 
 9.1% 27.3% 
2 2 61-65 
 9.1% 9.1% 
0 1 66-70 
 0 4.5% 
1 0 
weight in kg before 
starting treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>70 
 4.5% 0 
2 0 35- 40 kg 
 9.1% 0 
2 0 41- 45 kg 
 9.1% 0 
2 4 46- 50 kg 
 9.1% 18.2% 
8 8 51- 55 kg 
 36.4% 36.4% 
1 5 56- 60 kg 
 4.5% 22.7% 
4 3 61- 65 kg 
 18.2% 13.6% 
1 1 > 70 kg 
 4.5% 4.5% 
2 1 
Weight in kg after 
completing treatment 
(at day 30 of 
treatment) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not weighed, the 
patient died 9.1% 4.5% 
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Table (3-13) Hb % at day zero before starting treatment and at day 30 after completing 
treatment for the VL patients receiving different drug therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
3 1 35% - 40% 
 13.6% 4.2% 
3 0 41% - 45% 
 13.6% 0 
3 1 46% - 50% 
 13.6% 4.2% 
3 2 51% - 55% 
 13.6% 8.3% 
4 5 56% - 60% 
 18.2% 25.0% 
4 8 61% - 65% 
 18.2% 33.3% 
0 2 66% - 70% 
 0 8.3% 
1 0 76% - 80% 
 4.5% 0 
1 3 
Hb % at day 0 before 
starting treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81% - 85% 
 4.5% 16.7% 
2 1 46-50 
 9.1% 4.5% 
2 2 56-60 
 9.1% 9.1% 
3 2 61-65 
 13.6% 9.1% 
4 4 66-70 
 18.2% 18.2% 
4 3 71-75 
 18.2% 13.6% 
3 6 76-80 
 13.6% 27.3% 
0 3 86-90 
 0 13.6% 
2 0 91-95 
 9.1% 0 
2 1 
Hb% at day 30 after 
completing treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not investigated, the patient 
died 9.1% 4.5% 
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3.12- Liver state throughout treatment 
There was no liver enlargement before starting treatment for 54.5% of VL patients receiving SSG alone 
and 45.5% receiving the combination therapy of SSG And FL and. liver enlargement for the other 
patients was subsided within 1,2,3,4 weeks from starting treatment, but there was 13.6% and 9.1% of 
the tow groups respectively their liver enlargement did not relieved even after completion of treatment 
(table 3-14). 
3.13- Liver function tests ( billirubin, protein and enzymes) before and after treatment 
 
A considerable percentage of VL patients from the tow groups receiving different therapy had an 
abnormal billurubin, protein and enzymes before starting treatment. The change in liver function tests; 
billirubine, protein or enzymes for the tow groups of patients after treatment was so different and 
irregular (table 3-15). 
3.14- Patients' condition before and after treatment 
Before starting treatment 50% of group one VL patients receiving SSG only look well and not sick, 
31.8% were slightly sick, and 18.2% were severely sick with UTI, GIT upset and RTI. And 40.9% of 
group tows VL patients receiving combination therapy of SSG and FL look well and not sick, 31.8 were 
slightly sick, and 27.3% were severely sick with UTI, GIT upset and/or RTI. 
After treatment 90.9% of group one VL. patients receiving SSG Alone were not sick and 9.1% died, 
and for group two receiving the combination therapy, 90.9% were not sick, 4.5% slightly sick and 4.5% 
died (table 3-16). 
3.15- Blood urea before and after treatment 
Before starting treatment 90.9% of VL patients in group one receiving SSG had normal blood urea, and 
9.1% with abnormal blood urea, after 15 days, 90.9% with normal blood urea and 9.1% died, but after 
treatment 86.4% were with normal blood urea,4.5% showed abnormal blood urea and 9.1% died (table 
3-17). 
3.16- Patients condition after one month, two months, three months and six months from 
completing treatment 
There was no relapse for the VL patients of the tow groups receiving different therapy after one month, 
tow months, three months or six months after treatment. 
Only tow patients (9.1%) were died from group one VL patients receiving SSG during treatment, and 
one patient (4.5%) was died from group tow VL patients receiving SSG and FL during treatment (table 
3-18). 
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Table (3-14) Liver state throughout treatment for VL patients receiving different drug 
therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
12 10 No enlargement 
 54.5% 45.5% 
1 2 Enlargement relieved after 
one week 
 4.5% 8.3% 
1 2 Enlargement relieved after 
2 weeks 
 4.5% 9.1% 
2 3 Enlargement relieved after 
3 weeks 
 9.1% 13.6% 
1 2 Enlargement relieved after 
4 weeks 
 4.5% 9.1% 
3 2 Enlargement is not 
relieved 
 13.6% 9.1% 
2 1 
Liver 
state 
through 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
The patient died 
 9.1% 4.5% 
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Table (3-15) Liver function test ( billirubin ) at day zero before starting treatment and at 
day 30 after completing treatment for the VL patients receiving different drug therapy 
Drugs used for treatment 
 
Variable Group 
SSG SSG+FL 
13 7 Normal billirubin 
 59.1% 31.8% 
9 15 
40.9% 68.2% 
Liver function test 
(billirubin) at day 0 
 
 
 
Abnormal bilirubin 
 
  
12 13 normal billirubin 
 54.5% 59.1% 
8 8 Abnormal billirubin 
 36.4% 36.4% 
2 1 
Liver function test 
(billirubin) at day 30 
 
 
 
 
 
patient died 
 9.1% 4.5% 
13 12 normal protein 
 59.1% 54.5% 
9 10 
40.9% 45.5% 
Liver function test (protein) 
at day 0 
 
 
 
Abnormal protein 
 
  
15 9 Normal protein 
 68.2% 40.9% 
5 12 Abnormal protein 
 22.7% 54.5% 
2 1 
Liver function test (protein) 
at day 30 
 
 
 
 
 
Patient died 
 9.1% 4.5% 
12 14 Normal liver 
enzymes 
 54.5% 63.6% 
10 8 
Liver function test (liver 
enzymes) at day 0 
 
 
 
Abnormal liver 
enzymes 
 45.5% 36.4% 
15 13 Normal liver 
enzymes 
 68.2% 59.1% 
5 8 Abnormal liver 
enzymes 
 22.7% 36.4% 
2 1 
Liver function test (liver 
enzymes) at day 30 
 
 
 
 
 Patient died 
9.1% 4.5% 
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Table(3-16) Patient's condition at day zero before starting treatment and at day 30 after 
completing treatment for the VL patients receiving different drug therapy 
Drugs used for treatment 
 
Group Variable 
SSG SSG+FL 
11 9 Not sick 
 50.0% 40.9% 
7 7 Slightly sick 
 31.8% 31.8% 
4 6 
Patient's 
condition at 
day 0 
Severely sick with UTI,GIT 
upset, and/or RTI 18.2% 27.3% 
20 20 Not sick 
 90.9% 90.9% 
0 1 Slightly sick 
  4.5% 
2 1 
Patient's 
condition 
after 
treatment 
completion The patient died 
 9.1% 4.5% 
 
Table (3-17) Blood urea at day zero before starting treatment and at day 15 and at day 30 
after completing treatment for the VL patients receiving different therapy  
Drugs used for treatment Group Variable 
SSG SSG+FL 
20 22 Normal - 10-50 mg/dl 
 90.9% 100.0% 
2  
Blood urea at day 
0 before starting 
treatment 
 
Abnormal - >50 mg/dl 
 9.1%  
20 21 Normal 10-50 mg/dl 
 90.9% 95.5% 
2 1 
Blood urea at day 
15 of treatment 
Not investigated, the patient 
died 9.1% 4.2% 
19 20 Normal 10-50 mg/dl 
 86.4% 90.9% 
1 1 Abnormal >50 mg/dl 
 4.5% 4.5% 
2 1 
Blood urea at day 
30 after 
completing 
treatment 
Not investigated, the patient 
died 9.1% 4.5% 
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Table (3-18) Condition of the VL patients receiving different therapy after one month, 
two months, three months and six months from completing treatment 
Drugs used for treatmentGroup Variable 
SSG SSG+FL 
20 21 No relapse 
 90.9% 95.5% 
2 1 
Patient's condition 
after a month 
The patient died within the first 
month 9.1% 4.5% 
20 21 No relapse 
90.9% 95.5% 
2 1 
Patient's condition 
after 2 months 
The patient died within the first 
month 9.1% 4.5% 
20 21 No relapse 
90.9% 95.5% 
2 1 
Patient's condition 
after 3 months 
The patient died within the first 
month 9.1% 4.5% 
20 21 No relapse 
 90.9% 95.5% 
2 1 
Patient's condition 
after 6 months 
The patient died within the first 
month 9.1% 4.5% 
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3.17- Clinical improvement  
3.17.1- Fever Reduction: 
All VL patients were complaining from fever, Comparisons within groups. body temperature was 
significantly decreased at every examination during treatment. Fever is totally relieved within two 
weeks of treatment for all patients within the two groups.  
Comparing between the two groups in fever reduction using qui square there was no significant 
statistical difference between the two groups in fever reduction (table 3-19). 
3.17.2- Spleen Size reduction : 
Spleen size was significantly decreased at every assessment during treatment with the two groups (table 
9). And there was no significant statistical difference between the two groups in reducing spleen size at 
different periods of examination by using independent T- test to Compare between the two groups 
(table 3-20). 
3.17.3- Liver size reduction 
liver size was significantly reduced in patients whose liver size was enlarged, at every assessment 
during treatment with the two treatment regimens(table 14). By using independent T- test to Compare 
between the two groups, it was found that there was no significant statistical difference between drugs 
used and liver size reduction(table 3-21). 
3.17.4- Change in Hb % 
Hb % was significantly increased at every investigation throughout treatment with the two groups(table 
13). Using independent T- test to Compare between the two groups it was found that there was no 
significant statistical difference in Hb% changes between the two groups at different periods of 
investigation(table 3-22). 
3.17.5- Weight Change: 
Weight of the patients was significantly increased at every assessment throughout treatment with the 
two groups(table 12), Using independent T- test to Compare between the two groups it was found that 
there was no significant statistical difference in weight change between two groups at different periods 
of follow up(table 3-23). 
3.17.6- TWBC change 
TWBC was almost significantly increased at every investigation throughout treatment with the two 
treatment regimens(table 3-10). 
Using independent T- test to compare between the two groups it was found that there was no significant 
statistical difference in TWBC change between two groups at different periods of investigation (table 3-
24). 
3.17.7-  Patient's condition before and after treatment 
Table (3-16), indicated that there was a significant improvement in the patients condition within the two 
groups  At the end of treatment. 
Statistically, by using cross tabulation to compare between the two groups there was no difference in 
patient's condition improvement between the two groups (table 3-25). 
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Table (3-19) Fever reduction - Chi-Square for drug therapy used for treatment with fever 
reduction in the two groups. 
Fever through treatment Drugs used for 
treatment Relieved 
within 1 
week 
Relieved 
within 2 
weeks 
 
D.f
 
X2 
 
Sig. 
SSG 19 3 
SSG+FL 19 3 1 0.00 1.0 
Sig. = significance (if value < 0.05) 
Table (3-20) Spleen Size reduction - T-test to investigate the difference in the average of 
spleen size according to the groups of drug therapy applied to patients. 
Spleen 
size 
Groups N Mean Std. 
devia. 
T-value Sig 
 
Sp. Size 
day 0 
 
Sodium 
So.+Flu 
22 
22 
4.54 
6.18 
3.59 
5.27 1.20 0.236 
 
Sp. Size 
day 7 
 
Sodium 
So.+Flu 
22 
22 
2.90 
4.54 
2.74 
4.94 1.35 0.182 
 
Sp. Size 
day 15 
 
Sodium 
So.+Flu 
22 
24 
1.55 
3.90 
2.25 
4.52 2.09 0.043 
 
Sp. Size 
day 21 
 
Sodium 
So.+Flu 
22 
24 
1.20 
2.71 
1.85 
4.30 1.45 0.155 
 
Sp. Size 
day 30 
 
Sodium 
So.+Flu 
22 
24 
0.40 
1.85 
1.04 
3.79 1.65 0.106 
 
Sig. = significance (if value < 0.05) 
No significance = T- value > 0.05 
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Table(3-21) Liver size reduction - T-test to investigate the difference in the average of 
liver size according to the groups of drug therapy applied to patients. 
Liver 
enlargement 
Drugs 
used for 
treatment
N Mean Std. 
Devia
. 
T-
value 
Sig 
Liver 
enlargement at  
day zero 
 
Sodium. 
Sod.+ flu 22 
22 
2.09 
2.45 
3.23 
2.61 0.410 0.684 
 
Liver 
enlargement at 
day 7 
 
Sodium. 
Sod.+ flu 
22 
22 
1.22 
1.68 
1.79 
 0.739 0.464 
 
Liver 
enlargement at 
day 15 
 
Sodium. 
Sod + flu 
20 
21 
.85 
.95 
1.42 
1.49 0.224 0.824 
 
Liver 
enlargement at 
day 21 
 
Sodium. 
So.+ flu 
20 
23 
.60 
.57 
1.31 
1.28 0.070 0.944 
 
Liver 
enlargement at. 
day 30 
 
Sodium. 
Sod.+ flu 
20 
23 
.30 
.19 
.97 
.60 0.434 0.667 
Sig. = significance (if value < 0.05) 
No significance = T- value > 0.05 
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Table (3-22) Hb% change - T-test to investigate the difference in the average of Hb% 
according to the groups of drug therapy applied to patients. 
Variables Groups N Mean Std. 
devia.
T-value Sig 
Hb % day 
0 
SSG 
SSG+FL.
22 
22 
54.27 
65.04 
12.15 
12.18 2.93 0.005 
Hb % day 
15 
SSG 
SSG+FL.
22 
22 
61.20 
66.28 
13.78 
13.27 1.20 0.236 
Hb % day 
30 
SSG 
SSG+FL.
22 
22 
69.65 
72.71 
10.52 
11.37 0.89 0.377 
Sig. = significance (if value < 0.05) 
No significance = T- value > 0.05 
Table(3-23) Weight change - T-test to investigate the difference in the average of weight 
change according to the groups of drug therapy applied to patients 
Variables Groups N Mean Std. 
devia.
T-
value 
Sig 
Weight at 
day 0 
SSG 
SSG+FL.
22 
22 
50.04 
53.87 
10.91 
6.41 1.42 0.163 
Weight at 
day 7 
SSG 
SSG+FL.
22 
22 
47.93 
53.74 
14.74 
6.75 1.68 0.100 
Weight at 
day 15 
SSG 
SSG+FL.
22 
22 
52.30 
55.44 
10.55 
5.99 1.18 0.245 
Weight at 
day 21 
SSG 
SSG+FL.
22 
22 
52.80 
55.66 
10.24 
6.29 1.08 0.285 
Weight at 
day 30 
SSG 
SSG+FL.
22 
24 
53.32 
56.13 
10.15 
5.94 1.08 0.283 
Sig. = significance (if value < 0.05) 
No significance = T- value > 0.05 
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Table (3-24) TWBC change - T-test to investigate the difference in the average of 
TWBC according to the groups of drug therapy applied to patients. 
Variables Drugs 
used for 
treatment
N Mean Std. 
devia. 
T-
value 
Sig 
TWBC 
day 0 
SSG 
SSG+FL. 
22 
22 
2363.6
2672.7
921.4 
1389.8 0.86 0.390 
TWBC 
day 15 
SSG 
SSG+FL. 
22 
22 
4120.0
3442.8
3810.5
1005.7 0.787 0.436 
TWBC 
day 30 
SSG 
SSG+FL. 
22 
22 
3520.0
3752.3
1436.9
1760.2 0.462 0.647 
Sig. = significance (if value < 0.05) 
No significance = T- value > 0.05 
 
Table (3-25) Patient's condition - Cross tabulation for patient’s condition before and after  
treatment period with the two groups exposed to different drug therapy 
Drugs used for treatment Patient’s 
Condition 
Groups 
SSG SSG+FL 
Not sick 11 09 
Slightly 07 07 
Day zero 
Severely 04 06 
Not sick 20 20 
Slightly 00 01 
After 
treatment 
Completion 
Patient 
died 
 
02 
 
01 
 
 
 
 
 
 
 
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 60 -
3.17.8- Patient’s Condition after treatment completion 
After one, two, three and six months from completion of treatment there was no any relapse within the 
two groups(table 3-18), and statistically there was no difference in number of relapsed cases(table 26). 
3.18- Parasitological cure  
In comparisons between the two groups there was no significant difference in number of  patients for 
whom lymph gland puncture test, bone marrow puncture test or spleen puncture test was done for VL. 
diagnosis throughout treatment. Also there were no differences in number of patients who were 
parasitological cured (negative test) for lymph gland puncture, bone marrow puncture or spleen 
puncture between  the two groups throughout treatment (tables 3-27,3-28,3-29). 
3.19- Safety evaluation 
Many variables were considered to evaluate safety depending on the patient follow up, examination and 
investigations throughout treatment. 
Changes in complaints, blood urea, liver function test, chest x- ray and ECG throughout treatment 
determine side effects from different drugs used. 
3.19.1- Patient’s complaints 
Approximately Similar number of the patient's complaints among two Groups (table 3-30) 
3.19.2- Symptoms appeared after starting treatment 
The new symptoms appeared after starting treatment is shown in (table 3-31) and there was slightly 
difference between the two groups receiving different treatment. 
3.19.3- Drugs used during treatment 
Slight differences in number of drugs used during treatment among two groups (table 3-32). 
3.19.4- Blood Urea  
Slightly differences in number of cases of blood urea between groups at day 0 / 15 and day 30 (table 3-
17,3-33). 
3.19.5- Liver Function tests (protein, billirubin and enzymes) 
There was no significant statistical difference between the two groups in protein, billirubin and enzymes 
according to liver function test done throughout treatment(table 3-34). 
3.19.6- Chest X-Ray  
Chest X- ray of the liver and heart showed Slightly differences in numbers of patients Chest X-ray 
change before and after treatment among two groups through out treatment (table 3-35). 
3.19.7- ECG 
ECG showed Slightly differences in number of patients EGG result before starting treatment, at day 
(15) and after completing treatment within the two groups  through out treatment (table 3-36). 
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Table(3-26) Cross tabulation for patient’s condition after 1,2,3, and 6 months of 
treatment completion for the two groups exposed to different drug therapy 
Drugs used for treatment Date of 
condition 
Groups 
SSG SSG+FL 
After one 
month 
No relapse 
Died 
within 
treatment 
20 
 
 
02 
21 
 
 
01 
After two 
months 
No relapse 
Died 
within 
treatment 
20 
 
 
02 
21 
 
 
01 
After three 
months 
No relapse 
Died 
within 
treatment 
20 
 
 
02 
21 
 
 
01 
After six 
months 
No relapse 
Died 
within 
treatment 
20 
 
 
02 
21 
 
 
01 
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Table(3-27) Gland puncture test - cross tabulation for patient’s gland puncture test 
through out treatment period with the two groups exposed to different drug therapy 
Drugs used for treatment Time of Gland 
Puncture test 
Groups 
SSG. SSG+FL 
Positive 11 14 Day zero 
Negative 11 08 
Positive 2 04 
Negative 19 18 
Day 10 
Not done, 
patient 
died 
 
 
01 
 
 
00 
Positive 02 00 
Negative 19 21 
Day 15 
Not done, 
patient 
died 
 
 
01 
 
 
01 
Negative 20 21 Day 21 
Not done, 
patient 
died 
 
 
02 
 
 
01 
Negative 20 21 Day 30 
Not done, 
patient 
died 
 
 
02 
 
 
01 
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Table (3-28) Bone marrow aspirate - Cross tabulation for patient’s Bone marrow aspirate 
through out treatment period with the two groups exposed to different drug therapy 
Drugs used for treatment Bone 
marrow 
aspirate 
test 
Groups 
SSG SSG+FL 
Positive 10 07 
Negative 01 01 
Day zero 
Not done 11 14 
Positive 00 02 
Negative 10 04 
Not done 11 16 
Day 10 
Died 01 00 
Positive 00 01 
Negative 00 01 
Not done 20 19 
Day 15 
Died 02 01 
Negative 00 01 
Not done 20 20 
Day 30 
Died 02 01 
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Table (3-29) Spleen puncture Test - Cross tabulation for patient’s Spleen puncture test 
through out treatment period with the two groups exposed to different drug therapy 
Drugs used for treatment Spleen 
Puncture 
test 
Groups 
SSG SSG+FL 
Positive 01 01 Day zero 
Not done 21 21 
Negative 01 01 
Not done 20 21 
Day 10 
Died 01 00 
Negative 00 00 
Not done 20 21 
Day 15 
Died 02 01 
 
 
Table (3-30) Patient’s complaints on admission - Cross tabulation for patient’s 
complaints at day (0) with the two groups exposed to different drug therapy 
Drugs used for 
treatment 
Time Patient’s complaints 
SSG SSG+FL 
Fever only 10 12 
Fever+RT,GIT or 
UT infections 
 
08 
 
 
05 
 
Fever+headach/epista
xis 
 
04 
 
03 
Fever with other 
symptoms 
 
0 
 
02 
Day 
zero 
total 22 22 
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Table (3-31) Cross tabulation for patient’s symptoms appeared after starting treatment 
with the two groups exposed to different drug therapy 
Drugs used for 
treatment 
Symptoms appeared after 
starting treatment 
SSG SSG+FL 
No symptoms 08 08 
GIT symptoms 03 06 
RT Symptoms 06 03 
Fever+headache/epistaxis 01 01 
UTI symptoms 01 03 
GIT and RT symptoms 01 00 
Patient died 02 01 
Total 22 22 
 
 
Table (3-32) Cross tabulation for drugs used during treatment with the two groups 
exposed to different drug therapy 
Drugs used Drugs used during 
treatment 
SSG. SSG+FL. 
No drugs 17 10 
One drug 02 07 
More than one drug 03 05 
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Table (3-33) Cross tabulation for blood urea with the two groups exposed to different 
drug therapy 
Drugs used for 
treatment 
Blood 
Urea 
Variables 
SSG SSG+FL 
Normal 10-
50mg/dl 
 
20 
 
22 
At day 
zero 
Ab. >50 mg/dl 02 00 
Normal 10-
50mg/dl 
 
20 
 
21 
At day 15 
Not investigated 
Patient died 
 
02 
 
01 
Normal 10-
50mg/dl 
 
19 
 
20 
Ab. >50 mg/dl 01 01 
At day 30 
Patient died 02 01 
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Table (3-34) T-test to investigate the difference in the  liver function tests(billirubin, 
protein, enzymes) between the two groups receiving different drug therapy  
Variables Groups N Mean Std. 
devia. 
T-value Sig 
Billirubin 
day 0 
SSG 
SSG+FL. 
22 
22 
1.63 
1.62 
1.29 
0.49 0.040 0.968 
Billirubin 
day 15 
SSG 
SSG+FL. 
22 
22 
1.72 
1.50 
1.31 
0.58 0.049 0.956 
Protein 
Day 0 
SSG 
SSG+FL. 
22 
22 
1.40 
1.41 
0.50 
0.50 0.035 0.987 
Protein 
Day 30 
SSG 
SSG+FL. 
22 
22 
1.40 
1.62 
0.66 
0.57 0.049 0.965 
Enzymes 
Day 0 
SSG 
SSG+FL. 
22 
22 
1.45 
1.33 
0.50 
0.48 0.058 0.879 
Enzymes 
Day 30 
SSG 
SSG+FL. 
22 
22 
1.40 
1.45 
0.66 
0.58 0.158 0.568 
Sig. = significance (if value < 0.05) 
No significance = T- value > 0.05 
Table (3-35) Cross tabulation for chest X-ray before and after treatment with the two 
groups exposed to different drug therapy 
Drugs used for 
treatment 
Chest X-Ray Before and after 
treatment 
SSG SSG+FL 
Normal lung & heart X-ray before 
& after treatment 17 18 
abnormal heart X-ray before & 
after treatment 3 1 
Abnormal lung X-ray before & 
after treatment 0 1 
Abnormal heart  X- ray before 
treatment 0 1 
Patient died 2 1 
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Table (3-36) Cross tabulation for EGG result with the two groups exposed to different 
drug therapy 
Drugs used for 
treatment 
 
 
ECG 
 
Variable 
SSG SSG+FL 
Normal 21 18 
Abnormal - complete right bundle 
branch block 1 1 
Abnormal - sinus tachycardia 0 1 
Abnormal show tall tended TW - 
left ventricular hypertrophy 0 1 
ECG before 
starting 
treatment 
 
 
 
Abnormal show TW inversion 0 1 
Normal, no changes take place 18 14 
Abnormal changes show 
ventricular premature beats 1 0 
Abnormal changes show flat TW 0 1 
Abnormal changes show tall 
tended TW 1 0 
Abnormal changes show TW 
inversion 0 2 
From abnormal become normal 
ECG 0 2 
Still abnormal show TW inversion 0 1 
Still abnormal 0 1 
ECG after 
15 days 
 
 
 
 
 
 
 
 
Patient died 2 1 
Normal, no changes take place 17 16 
Abnormal changes show TW 
inversion with atrial ectopics 0 1 
From abnormal become normal 
ECG 1 1 
Still abnormal changes show TW 
inversion  0 2 
Abnormal changes show sinus 
bradycardia 1 0 
Still abnormal changes 1 1 
ECG after 
completing 
the 
treatment 
 
 
 
 
 
 
Patient died 2 1 
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3.20- Mortality 
There was no significant difference in mortality rate between the two groups, two patients died during 
treatment from group A receiving SSG alone and one patient from group two receiving combination 
therapy SSG and fluconazole, mortality rate equal 9.1% and 4.5% respectively which is within the  
normal range of mortality rate among the VL. patients in geared teaching hospital (table 3-37). 
Table (3-37) Cross tabulation for mortality rate within the two groups exposed to 
different drug therapy 
Drugs used for 
treatment 
Patient condition 
SSG SSG+FL 
Not sick 20 20 
 
Slightly sick 00 01 
Patient Died 02 01 
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Picture no. (3-1) Severely ill VL patient before starting treatment   
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Picture no. (3-2) Severely ill VL patient receiving supportive treatment in Gadaref 
teaching hospital 
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Picture no.(3-3) VL patient receiving a dose of I.V injection of SSG  
in Gadaref teaching hospital 
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Picture no.(3-4) Asymptomatic VL patients after two weeks from starting treatment 
stayed in Gadaref Teaching hospital to complete the treatment  
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Picture no.(3-5) PKDL patient in Gadaref Teaching hospital-1 
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Picture no.(3-6) PKDL patient in Gadaref Teaching hospital-2 
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CHAPTER FOUR 
DISCUSSION 
 
In this hospital based clinical study, 22 patients with VL could be enrolled into each treatment arm 
(total 44 patients). With this number, we thought it unlikely that we would be able to demonstrate 
significant differences in efficacy, but it was considered a satisfactory balance between scientific 
purposes and practical constraints 
Because of the criteria for inclusion and the limited number of women at risk for leischmania in the 
study areas, we had no female patients in our study, generally fewer percentage of reported cases of 
visceral leischmaniasis in Gadaref state occur among women. 
We anticipated a low rate of loss to follow-up, because visceral leischmaniasis primarily affects 
construction workers and farmers (almost 50 percent of the patients were in the productive age between 
25 to 40 years old (table 3-4), who are frequently unable to keep their follow-up appointments because 
of work or financial constraints. Although a number of patients were lost to follow-up, the net number 
of patients that were closely followed up was statistically significant who are equal to > 10% of total 
number of V.L patients in Gadaref Teaching  Hospital. (Table 3-2). 
To fulfill the objectives of the study, different parameters were used; including clinical improvement, 
parasitological cure, side effects and mortality rate so as to evaluate the advantages of the combination 
therapy SSG+FL over the single drug monotherapy SSG.  
At last we are looking for the benefits of using the combination FL with SSG in treatment of VL so as 
to minimize the duration of treatment, decrease the overall cost of treatment and to control patient 
compliance and hospitalization period. 
Parasitological definitions of efficacy were cure (negative aspirates for leischmania amastigotes after 
starting treatment), and not cure (positive aspirates for leischmania amastigotes after starting treatment). 
 
4.1- VL in Gadaref State  
The total number of VL cases in Gadaref State in the last four years; 2005, 2006, 2007 and 2008  is so 
high (average 3239 patients per year), it is almost equal to VL patients total number in late nineteenth; 
1996 to 2000 which were 13000 cases (Thomson M, Connor S, 2000) 
Relapse among VL patients was increased when compared between 2006 – 2007 and 2007 – 2008 
(Tables 3-3A, 3-3B) which indicate the presence of resistance to SSG in Gadaref State, compared with 
the situation in other areas a decline in efficacy of SSG occurred in endemic areas of Bihar in India that 
has rendered this drug useless in this region (Murray, H. 2001).  
Mortality rate is so high and average in years 2005, 2006, 2007 and 2008 reached 3.85 % in Gadaref 
state and 4.15 in Gadaref Teaching Hospital, although there are no studies explaining this high mortality 
rate but it is probably due to late diagnosis, complications of the disease and treatment difficulties. And 
commonly without proper treatment the mortality rate for kala-azar is close to 100% and  diagnostic 
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difficulties arose from inexperience with the disease, long incubation period and the wide differential 
diagnosis. And misdiagnosis is dangerous (Berman Jd.1997).  
With the recent introduction of new drugs, the main limits in reducing deaths from visceral 
leischmaniasis are difficulty in diagnosis in the field and health inequality and patients lack of access to 
treatment (Berman J, 2003). 
Due to high number VL patients in Gadaref state it was chosen to conduct a programme against the 
disease started in April 1999 by Médecins Sans Frontières Holland (MSF-Holland) (Thomson M, 
Connor S, 2000) 
 
4.2- Treatment of VL in Gadaref State 
There was not several treatment options exists in Gadaref state, even in Sudan for VL. This will 
diminish dependence on the consideration of the different factors affecting the chose of appropriate 
drug As it was stated that many factors must be taken in account while choosing the most appropriate 
agent for the therapeutic management of VL; include not only medical factors such as the clinical 
features of the disease, drug safety, efficacy and cost but also socio-economical and cultural factors 
(Berman J. 2003)   
Only two treatment options exist for VL in Gadaref state, which include expensive injectable 
medications SSG and lipid AMB. For the clinician, the choice of treatment is very restricted either to 
use sodium stilbogluconate for the new infections, which is brought by the WHO concerned 
organizations worked in the determined area, or to avail amphotericin B from donors in Khartoum for 
the treatment of relapsed cases (Reports of the Department of Medicine, Gadaref teaching hospital, 
Ministry of Health, Gadaref State, Sudan). 
VL treatments need hospitalization and follow up and available treatment options, both SSG and AmB 
have to be administered parentally for prolonged period of time. which render VL treatment difficult 
(Murray, H. 2001). 
Moreover lipid formulations of Amp B are a major advance in the treatment of VL; however, their 
prohibitive cost puts them beyond the reach of most patients (Agrawal S, et al. (2005) 
Jose Antonio Bastos, The aid agency Médecins Sans Frontiàres, operational director for Sudan, said: 
"It's shameful we are treating a deadly disease with a very toxic drug that comes from the 1950s. We're 
putting pressure on the pharmaceutical industry for research for [cheap] drugs and diagnostic tests for 
kalaazar."(Sundar.etal.2002). 
Antimony resistant strains of L. donovani were also wide spread over different geographical areas, and 
considerable number of relapsed VL cases existed in Gadaref state after receiving sodium 
stilbogluconate. (Reports of Ministry of Health, Gadaref State, Sudan).  
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4.3- The study drug (FL) 
As far as can be ascertain, this is the first trial in which the combination of FL plus SSG against VL was 
evaluated, however, some studies produced limited data on the efficacy of FL used alone against VL, or 
used alone or in combination against CL.( (Agrawal S et al. 2005).  
Lamya Alnaim. And co-workers in. 2007 carried out study about the effects of FL on the 
pharmacokinetics and pharmacodynamics of antimony in CL-infected hamsters; the results of this study 
have consistently shown the existence of a potential pharmacokinetic interaction between FL. and SSG. 
This result ensures the need of this clinical study outcome so as to correlate between the 
pharmacokinetic interactions and the clinical interaction between the combination of  FL and SSG. 
Activity of FL. against VL was described in a report on 20 patients with Indian KA who received FL, in 
11 of whom the disease was apparently cured, by clinical and parasitological standards. However, all 
patients eventually had a relapse and were treated with antimony ( Sundar et al, 2002).  
FL is found effective in treatment of CL, a Randomized double-blind placebo-controlled trial assessed 
the efficacy of oral FL, in a dose of 200 mg daily for six weeks, in the treatment of parasitological 
confirmed cutaneous leischmaniasis, was conducted in Saudi Arabia. It was found that a six-week 
course of oral fluconazole is a safe and useful in treatment for cutaneous leischmaniasis caused by L. 
major. (Zvulunov A. et al, 2002). 
FL has also been used successfully in combination with allopurinol to treat visceral leischmaniasis in 
immunocompromised patients, a case of visceral leischmaniaisis and renal insufficiency was reported to 
be treated successfully with FL and allopurinol for 4 months (Colakoglu M. et al. (2006).   
The other azoles that had been studied for the treatment of CL and VL of the Old World were 
metronidazole, ketoconazole and itraconazole. ( Lafeuillade A. et al, 1992) (Laguna del Estral, et 
al,1994). 
 
4.4- Diagnosis of VL 
Diagnosis is based on the symptoms and clinical signs of VL which are not enough to differentiate VL 
from other similar conditions such as malaria which is very common in Gadaref state. Definitive 
diagnosis of visceral leischmaniasis requires detection of Leischman-Donovan bodies (amastigotes) in 
stained tissue samples, by examining enlarged lymph nodes, bone marrow aspirates or splenic aspirates 
which have the highest yields but may be risky (Ritmeijer K. 2006). 
The most typical symptoms of VL include high fever with common  clinical sings which include 
spleenomegaly, hepatomegaly and lymphadenopathy and the other symptoms are very easy to mistake 
for those of malaria, the disease is usually complicated by serious secondary infections, haemolytic 
anemia, acute renal damage and severe mucosal hemorrhage  which often contribute to the high fatality 
rate of VL patients (Berman J. 2005), that is why confirmation of diagnosis is the stone corner  to start 
treatment. 
Lymph gland puncture is almost the main parasitological investigation for diagnosis in Gadaref 
Hospital although it gives positive results in 60% of V.L patients (Reports of the Department of 
Medicine, Gadaref teaching hospital, Ministry of Health, Gadaref State, Sudan).  
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Diagnostic difficulties arose from inexperience with the disease, long incubation period and the wide 
differential diagnosis, Misdiagnosis is dangerous, as without proper treatment the mortality rate for 
kala-azar is close to 100% (Berman Jd.1997).  
Bone marrow aspirate and spleen puncture test are available alternatives for diagnosis. Parasitological 
diagnosis is the most important in diagnosis of visceral leischmaniasis, because the symptoms of V.L. is 
not typical and the differential diagnosis are various and different. 
Parasitaemia was used as a useful indicator in determining the efficiency of the treatment against 
visceral leischmaniasis and it is used in different clinical studies to determine the cure rate of VL. 
Although looking for VL parasites in the spleen and liver is one of the most accurate methods available 
to determine leischmanial infections, and ninety percent of the active cases show parasites in spleenic 
and liver aspirates (Manson-Bahr, 1987) but gland puncture test which is an easy and economical 
procedure of diagnosis in Gadaref teaching hospital, was commonly used  
 
4.5- Combination treatment evaluation 
Because treatment with antimony agents is associated with side effects, resistance and with the 
inconvenience of parenteral administration, there has been a demand for oral alternatives, no quite 
enough drugs are currently in the early stages of development, so there are good reasons for the use of 
combination therapy; to prevent further development of resistance against the limited therapeutic 
options available (M. Ouellette et al. 2004)  
In view of the emergence of parasite resistant to antileischmanial drugs, and limited number of effective 
antileischmanial drugs, there is an urgent need to revise the strategy of treatment. Combination therapy 
with multiple drugs is a viable option, which needs to be given serious consideration (Agrawal S et al. 
2005). 
Discovery, development and registration of oral miltefosine for the treatment of VL in India and the 
likely approval of paromomycin and further development of oral sitamaquine will, for the very first 
time, provide an opportunity to clinicians to look at the combination chemotherapy of VL thus 
providing a safe and effective shorter course of treatment which would also be affordable (Shyam 
Sundar & Mitali Chatterjee 2006) 
In addition to the combination under study, other different combinations are discussed and seriously 
considered; these include miltefosine plus paromomycin and allopurinol plus an azole. Lessons may be 
learnt from the experiences of similar problems in malaria, leprosy and tuberculosis (Bryceson, 
Anthony ( 2001). 
4.5.1- Efficacy Evaluation 
The primary parameter of efficacy was final cure which include clinical improvement and 
parasitological cure persisting at different periods after starting treatment. 
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• Clinical improvement 
Clinical improvement was defined as improvement in one or more clinical signs, such as increase in 
body weight, reduction in fever and reduction in spleen and in liver sizes. 
The rapid and significant decrease in fever, spleen and liver sizes among the tow therapeutic regimens 
showed the efficient response to treatment because the most typical symptoms of VL are fever and the 
enlargement of the spleen with enlargement of the liver (Hashim et al, 1994). 
Generally weight of the patients within tow groups was increased; rate of increment among the patients 
was different according to individual variation of the patient, disease and social factors. VL disease is 
associated with different symptoms affecting the weight and causing weight loss such as; fatigue, poor 
appetite, insomnia, abdominal pain, anorexia, and diarrhea (Hashim et al, 1994). 
There was no significant difference between the VL Patients within the two groups receiving single 
SSG or the combination of SSG and FL In resolution of fever, reduction of spleen size, reduction of 
liver size and weight change. 
The patients condition improvement after treatment was good and at the end of treatment patients were 
completely recovered and no complications or relapse occurred during six months of follow up and 
there were no significant differences between the two groups, this will support the high efficient VL 
treatment and most patients will recovered if treated properly ((V. Vanlerberghe, et al. 2007) 
During this study various clinical features of VL patients was presented, which include severely ill 
patients, healthy patients and PKDL (picture 3-1,3-2,3-5,3-6) that is why During treatment and along 
the different stages of recovery, strong friendship is built up between the patients and the staff who was 
fully co-operative and helpful (picture 3,4). This situation facilitates the accurate study follow up and 
completion.  
• Biochemical investigations 
The increase in Hb % and TWBC was obvious and significant among the patients within tow groups 
after treatment, decrease in Hb% and TWBC is associated with VL disease laboratory findings which 
include; Anemia, leukopenia, thrombocytopenia, hyperglobulinemia, and hypoalbuminemia 
(Goldsmith, R.S. 1999). And it was found that there was no significant statistical difference in Hb% 
changes and in TWBC change between the tow groups after treatment.  
• parasitological cure  
Gland puncture test was done first for all VL patients on admission, Bone marrow aspirate was used for 
those who were negative to gland puncture test because bone marrow aspirate give positive results in up 
to 80% of the cases and Lymph gland puncture test gives positive results in 60% of the cases (Williams, 
1995). If bone marrow aspirate failed to give positive result, spleen puncture test would be used which 
yield a positive result in 90 % of the cases (Williams, 1995), this spleen puncture test was done for only 
one patient in each group and gland puncture test was done for nearly 5o % of the patients (tables 3-
27,3-28,3-29). 
In comparisons between the two groups there was no significant difference in parasitological cure and 
after ten days more than 90 % of the two groups were cured, but 100% were cured within 21 days 
(tables 3-27,3-28,3-29).so parasitological cure rate between the tow groups is nearly the same. 
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• mortality rate  
Mortality rate this study is almost normal when compared with the average mortality  in Gadaref 
Teaching Hospital, and the high percent of mortality occur among VL that received monotherapy SSG, 
which indicate that the combination of FL with SSG had no effect on mortality among VL patients in 
this study (Reports of the Ministry of Health, Gadaref State, Sudan) 
 
4.5.2- Safety Evaluation 
Safety evaluation which is an important parameter was used to compare between the two groups 
receiving the monotherapy SSG and the combination therapy SSG + FL.  
Many variables were considered to evaluate safety depending on the patient follow up, examination and 
investigations done throughout treatment. 
The slight difference in symptoms appeared after starting treatment and drugs used during treatment, 
among VL patients within the two groups, which were not significant, is probably due to variable drugs 
used and individual variation in response to drugs. 
Blood urea slight difference between the two groups, although it is not significant but it also 
irrespective of drugs used for the two groups because important abnormal blood urea result was present 
on admission before treatment started. 
Although chest x-ray slight changes between the two groups is not significant but it mostly seems 
irrespective of  drugs used for the two groups because chest x-ray changes were not complied with the 
expected ones according to drugs used, FL. was expected to prolong QT interval in the ECG result 
(FL.1996-2001. Medicine Net, Inc.) And this was not take place in the ECG findings after treatment. 
 
The study drug FL was assessed in combination with SSG against SSG alone by using efficacy and 
safety evaluation parameters. (Colakoglu M, et al. 2006) and the outcome was probably similar 
including the clinical improvement, parasitological cure, side effects and mortality rate. 
The similar clinical improvement between the two groups receiving monotherapy SSG and combination 
therapy SSG + FL was shown by the same outcomes in  resolution of fever, increase in TWBC, 
increases in Hb percent, regression of spleen size, regression of liver size, weight change and parasite 
clearance. 
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CHAPTER FIVE 
 
CONCLUSION AND RECOMMENDATIONS 
5.1- conclusion 
This hospital based study was done in Gadaref State, in which visceral leischmaniasis is a medical 
problem because of increasing relapse and treatment difficulties. The study is an attempt to find out a 
solution for VL treatment by introducing an oral drug (FL) to be combined with SSG so as to decrease 
relapse and to overcome the disadvantages of using the single expensive I.V injectable long duration 
drug against V.L. 
 
The present result showed that fever resolution , TWBC improvements, Hb% improvements, spleen size 
regression, liver size regression, weight change and parasite clearance was similar within the two 
groups who were receiving SSG alone or SSG in combination with FL  in treatment of VL. 
 
Hence SSG combined with FL produced approximately similar clinical improvement, parasitological 
cure, side effect and mortality rate to VL patients using monotherapy SSG 
As a result the combination therapy of FL and SSG against VL was found to have no significant 
advantages over the single drug SSG, and there would be no change in the duration of treatment, over 
all cost of treatment and hospitalization period. And also no expected significant advantages to manage 
and control resistance in the future. 
So, it was concluded that there is no significant advantages of the combination therapy of FL and SSG 
over the single drug SSG, and there would be no need to use the combination therapy instead of the 
single therapy SSG.  
5.2. Recommendations 
The data collected and presented in this thesis would support the following recommendations:- 
1) SSG remains the only drug available in treatment of Kalazar in Gadaref hospital, so rational 
drug use should be followed concerning accurate dose concentration and appropriate duration of 
treatment so as to prevent relapse and resistance. 
2) AmB, which is the first-line drug now used in treatment of relapsed cases, should have been 
available in practice through the different possible routes in an economical affordable price. 
3) Different treatment alternatives are recommended according to the resistance pattern, so 
Efforts should be undertaken in Identifying and registering miltefosine as an effective oral                 
therapy for this neglected VL. 
     4)    Further clinical studies are essential to look for alternative oral combination therapy. 
 
 
 
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 83 -
 
 
CHAPTER SIX 
REFFERENCES 
Allain DS, Kagan IG.(1975). A direct agglutination test for leischmaniasis. Am J Trop Med Hyg ;24: 
232-6  
Anuradha Dube.(2007) Proteomic approach for identification and characterization of novel   
immunostimulatory proteins from soluble antigens ofLeishmania donovani promastigotes. 
PROTEOMICS 7:5, 816 
 
Ahuja, S. S., Mummidi, S., Malech, H. L., Ahuja, S. K.(1998). Human Dendritic Cell (DC)-Based Anti-
Infective Therapy: Engineering DCs to Secrete Functional IFN-{gamma} and IL-12. J Immunol 161: 
868-876  
Am J Trop Med Hyg.(2005). Recent understanding in the treatment of visceral leishmaniasis. 
Infectious Diseases.72(3):359 
Allison EJ; McKinney TJ; Langenberg JN. (2002). Biopharm Drug Dispos. 23(2):59-66  
 
Alrajhi AA; Ibrahim EA; De Vol EB; Khairat M; Faris RM; Maguire JH. (2002). Fluconazole for the 
treatment of cutaneous leishmaniasis caused by Leishmania major, N Engl J Med.346(12):891-5 
Alrajhi AA; Ibrahim EA; De Vol EB; Khairat M; Faris RM; Maguire JH. (2005). Management of 
visceral leishmaniasis: Indian perspective. Journal of Postgraduate Medicine, 51( 5) pp. 53-57  
Ashford RW, Thomson MC,(1991). Visceral leishmaniasis in Sudan: a delayed development 
disaster? Ann Trop Med Para-sitol 85: 571–572  
Ashford RW, 1974. Sandflies (Diptera: Psychodidae) from Ethiopia: taxonomic and biological notes. J 
Med Entomol 11: 605–616.  
Ashford RW,(1996). Leishmaniasis reservoirs and their significance in control. Clin Dermatol 14: 523–
532. 
Berhe N; Abraham Y; Hailu A; Ali A; Mengistu G; Tsige K; 
Abebe Y;.( 2001).Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for 
visceral leishmaniasis. East Afr Med J. 78(11):608-10 
 
Berman J.(2005). Clinical status of agents being developed for leishmaniasis. Expert Opin Investig 
Drugs.14(11):1337-46 
 
Berman J. (2003). Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16(5): 397-401 
Berman JD. (1997). Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in 
the last 10 years. Clin Infect Dis 24(4): 684-703  
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 84 -
Bergquist NR,(2001). Vector-borne parasitic diseases: new trends in data collection and risk 
assessment. Acta Trop 79: 13–20.  
 
Bodey GP. (1992). Azoles antifungal agents. Clin Infect Dis; 14 Suppl 1: S161-S169 
Bryceson, Anthony ( 2001). Tropical Medicine & International Health. 6: 928-934. 
Badaro R, Benson D, Eulalio MC, Freire M, Cunha S, Netto EM, et al. rK39.(1996) a cloned antigen 
of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis;173: 758-61.  
Boelaert M, Lynen L, Desjeux P, Van der Stuyft P.(1999). Cost-effectiveness of competing 
diagnostic-therapeutic strategies for visceral leishmaniasis. Bull World Health Organ;77: 667-74.  
 
Colakoglu M; Yaylali GF; Colakoglu NY; Yilmaz M. (2006). Successful treatment of visceral 
leishmaniasis with fluconazole and allopurinol in a patient with renal failure..Scand J Infect 
Dis.38(2):152-4 
Chappuis F, Mueller Y, Nguimfack A, Rwakimari JB, Couffignal S, Boelaert M, et al.(2005) 
Diagnostic accuracy of two rK39 antigen-based dipsticks and the Formol Gel test for the rapid 
diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol;43(12): 5973-7. 
C.P. Thakur, T.P. Kanyok, A.K. Pandey, G.P. Sinha, A.E. Zaniewski, H.H. Houlihan, P. Olliaro 
(2000). A prospective randomized, comparative, open-label trial of the safety and efficacy of 
paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the 
treatment of visceral leishmaniasis. Tropical medicine and hygene, 94: 429-431 
Desjeux P,(1996). Leishmaniasis: public health aspects and control. Clin Dermatol 14: 417–423.  
Deeks JJ, Altman DG, Bradburn MJ.(2001). Statistical methods for examining and combining results 
from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic 
reviews in health care. London: BMJ books, 285-311.  
Deeks JJ.( 2001). Systematic reviews of evaluations of diagnostic and screening tests. BMJ;323: 157-
62.  
Deeks JJ.(2001). Systematic reviews of evaluations of diagnostic and screening test. In: Egger M, 
Davey Smith G, Altman DG, eds. Systematic reviews in health care. London: BMJ books, 248-82.  
Desjeux P.(2001).The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med 
Hyg;95:239–43.  
Desjeux P.(2001). The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal 
Society of Tropical Medicine and Hygiene,95:239-342 
 
Dictionary definition of fluconazole. (2004). The American Heritage Dictionary of the English 
Language, Fourth Edition. Published by Houghton Mifflin Company. 
 
Desjeux P.( 2001). The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal 
Society of Tropical Medicine and Hygiene,95:239-342 
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 85 -
De La Rosa R, Pineda JA, Delgado J, et al.( 2002). Incidence of and risk factors for symptomatic 
visceral leishmaniasis among HIV type 1-infected patients from Spain in the era of HAART. J Clin 
Microbiol, 40:762-7.  
De Wit S, Goossens H, Weerts D, et al. (1989). Comparison of fluconazole and ketoconazole for 
oropharyngeal candidiasis in AIDS. Lancet; 1: 746-8. 
Eur J Clin (2005). Microbiol Infect Dis.24(6):411-8 
Elnaiem DA, Hassan MM, Maingon R, Nureldin GH, Mekawi AM, Miles M, Ward RD.(2001). The 
Egyptian mongoose, Her-pestes ichneumon, is a possible reservoir host of visceral leishmaniasis in 
eastern Sudan. Parasitology 122: 531–536.  
El-Hassan AM, Zijlstra EE, Ismael A, Ghalib HW,(1995). Recent observations on the epidemiology of 
kala-azar in the eastern and central states of the Sudan. Trop Geogr Med 47: 151–156.  
Elnaiem DA, Hassan HK, Ward RD,(1997). Phlebotomine sand-flies in a focus of visceral 
leishmaniasis in a border area of eastern Sudan. Ann Trop Med Parasitol 91: 307–318.  
Elnaiem DA, Ward RD, Hassan HK, Miles M, Frame I,(1998). Infection rates of Leishmania donovani 
in Phlebotomus orien-talis. Ann Trop Med Parasitol 92: 229–232.  
Elnaiem DA, Thomson M, Mukhtar M, Hassan HK, Aboud MA, Conner S, Ashford RW,(1998). 
Environmental determinants of the distribution of the vector of kala-azar in Sudan. Ann Trop Med 
Parasitol 92: 877–887.  
E.E. Zijlstra, E.A.G. Khalil, P.A. Kager, A.M. El-Hassan. (2000). Post-kala-azar dermal 
leishmaniasis in the Sudan: clinical presentation and differential diagnosis 
British Journal of Dermatology, 143:136 – 143 
Elnaiem DA, Hassan HK, Ward RD,(1999). Association of Phlebotomus orientalis and other sandflies 
with vegetation types in the eastern Sudan focus of kala-azar. Med Vet Entomol 13: 198–203.  
Eur J Clin Microbiol Infect Dis.(2005). Leishmaniasis as an opportunistic infection in HIV-infected 
patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a 
Mediterreanean region; 0934-9723. 
Fernandez-Cotarelo MJ, Abellan Martinez J, Guerra Vales JM, et al.( 2003). Effect of highly active 
antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human 
immunodeficiency virus-infected patients. Clin Infect Dis, 37: 973-7.  
Gagnaire, M.-H., Galambrun, C., Stéphan, J. L. (2000). Hemophagocytic Syndrome: A Misleading 
Complication of Visceral Leishmaniasis in Children---A Series of 12 Cases. Pediatrics 106: 58e-58     
Gasser RA, Jr., Magill AJ, Oster CN, et al.(1994) Pancreatitis induced by Pentavalent antimonials 
agents during treatment of leishmaniasis Clin Infect Dis 18:83-90.  
Gradoni L, Scalone A, Gramiccia M.( 1996). Epidemiological surveillance of leishmaniasis in HIV-1-
infected individuals in Italy. AIDS;10:785–91.  
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 86 -
Hailu A, Kroon CC, Schoone GJ, Berhe N, Schallig HD, Kager PA.(2002). Seroepidemiological 
assessment and diagnosis of visceral leishmaniasis in an endemic locality using fast agglutination 
screening test (FAST). Acta Trop;83: 93-101.  
Hoogstraal H, Heynemann D,(1969). Leishmaniasis in the Sudan Republic. 30. Final epidemiological 
report. Am J Trop Med Hyg 18: 1091–1210.  
Ho M, Siongok TK, Lyerly WH, Smith DH.(1982). Prevalence and disease spectrum in a new focus 
of visceral leishmaniasis in Kenya. Trans R Soc Trop Med Hyg;76:741-746.  
 
Henry W. Murray. (April 2004). Progress in the treatment of a neglected infectious disease: visceral 
leishmaniasis. Expert Review of Anti-infective Therapy Vol. 2, No. 2, Pages 279-292  
Ill KM, O'Brien WCah.(1989) Tropical Medicine A Clinical Text. Mount Salus Press, Dublin, p33-34.  
Indu B. Ahluwalia, et al, (2004). Visceral Leishmaniasis: Consequences to Women in a Bangladeshi 
Community.J Womens Health 13(4):360-364 
 
Jean-Pierre Gangneux, et al. (1996). Therapy of Visceral Leishmaniasis Due to Leishmania infantum: 
Experimental Assessment of Efficacy of AmBisome. Antimicrobial agent and chemotherapy, 40: 1214–
1218. 
 
J. M. Blackwell, G. F. Black, C. S. Peacock, E. N. Miller, D. Sibthorpe, D. Gnananandha, J. J. 
Shaw, F. Silveira, Z. Lins-Lainson, F. Ramos, (1997) Immunogenetics of leishmanial and 
mycobacterial infections: the Belem, 352: 1331-1345. 
 
Jean-Pierre Gangneux, Michael Dullin, Annie Sulahian, Yves Jean-Francois Garin, and Francis 
Derou, (1999). Experimental Evaluation of Second-Line Oral Treatments of Visceral Leishmaniasis 
Caused by Leishmania infantum. Antimicrobial Agents and Chemotherapy, January 43: 172-174 
.Johan van Griensven, Marleen Boelaert, Institute of Tropical Medicine, Antwerp, Belgium. 
Combination therapy for visceral leishmaniasis: why, what and where?) 
 
Killick-Kendrick R,(1990). Phlebotomine vectors of leishmaniasis: a review. Med Vet Entomol 4: 1–24 
  
Laurie Barclay, MD. (2002).Miltefosine Safe, Effective in Visceral Leishmaniasis. N Engl J Med. 
347(22):1737-1738, 1739-1746, 1793-1794 
Laguna F, Lopez-Velez R, Pulido F, et al.( 1999). Treatment of visceral leishmaniasis in HIV-infected 
patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS, 13:1063-9.  
L. Alnaim, N. Abou Alsoud, I. Zaghloul, M. AL-Jaser. Effects of fluconazole on the pharmacokinetics 
and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters, International 
Journal of Antimicrobial Agents, Volume 29, Issue 6, Pages 728-732 
 
Margriet den Boer and Robert N Davidson. (April 2006). Treatment options for visceral 
leishmaniasis. Expert Review of Anti-infective Therapy. Vol. 4, No. 2, P. 187-197  
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 87 -
Mansueto S, Barba G, Cerrito B, Farinella E, Orsinis S, Di Rosa S.( 1987). Visceral leishmaniasis 
of adults in Sicily: a truce interrupted? Trans R Soc Trop Med Hyg;81:161–2  
 
M. Ouellette, J. Drummelsmith, B. Papadopoulou. (2004). Leishmaniasis: drugs in the clinic, 
resistance and new developments. Elsevier, 7(4):257-266 
Murray, H. W. (2001). Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. 
Antimicrob. Agents Chemother. 45: 2185-2197.   
Mabey D, Peelin RW, Ustianowsk A, Perkin MD.(2004). Tropical infectious diseases: diagnostics for 
the developing world. Nat Rev Microbiol;2: 231-40.  
 
Mary Ann Liebert, Inc.( 2004).Journal of Womens Health. 13(4):360-364  
Medecins Sans Frontieres-Holland, Amsterdam, the Netherlands Centers for Disease Control 
and Prevention, Atlanta, GA 30341-3724 
Newcombe RG.(1998). Two-sided confidence intervals for the single proportion: comparison of seven 
methods. Stat Med;17: 857-72.  
Nicolas Mbongo, Philippe M. Loiseau, Marie A. Billion, and Malka Robert-Gero, (1998). 
Mechanism of Amphotericin B Resistance in Leishmania donovani Promastigotes. Antimicrobial 
Agents and Chemotherapy, 42: 352-357. 
Oren R, Schnur LF, Ben Yehuda D, Mayner V, Okon E, Rachmilewitz EA. (1991). Visceral 
leishmaniasis: a difficult diagnosis and unusual causative agent. J Infect Dis. 164: 746-9. 
 
Pasquau F; Ena J; Sanchez R; Cuadrado JM; Amador C; Flores J; Benito C; Redondo C; 
Lacruz J; Abril V; Onofre J;.(2005). Leishmaniasis as an opportunistic infection in HIV-infected 
patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a 
Mediterreanean region. Eur J Clin Microbiol Infect Dis. 24(6):411-8 
Pharmacy information about fluconazole. (1996-2001). MedicineNet, Inc. 
Philippe Hantson, M.D., Ph.D., Samuel Luyasu, M.D., Vincent Haufroid, B.Sc.(Pharm.), M.S., and 
Michel Lambert, M.D., Ph.D.(2000). Antimony excretion in a Patient with Renal Impairment During 
Meglumine Antimoniate, pharmacotherapy Publications 20(9):1141-1143 
Pampiglione S, Manson-Bahr PEC, Giungi F, Giunti G, Parenti A, Canestri TG.(1974) Studies on 
Mediterranean Leishmaniasis, Asymptomatic cases of visceral leishmaniasis. Trans R Soc Trop Med 
Hyg 1974;68:447-453.  
Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E.( 2001). Visceral leishmaniasis in 
HIV-infected and non-HIV-infected patients. A comparative study. Medicine, 80:54-73. 
P . Olliaro , P . Guerin , S . Gerstl , A . Haaskjold , J . Rottingen , S . Sundar, (2004). Treatment 
options for visceral leishmaniasis. Lancet Infectious Diseases ,  5: 763 - 774  
Quate LW,(1964). Phlebotomus sandflies of the Paloich Area in the Sudan (Diptera, Psychodidae). J 
Med Entomol 1: 213–268  
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 88 -
Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O'Keeffe C, Davidson RN.(2006). Evaluation of a 
new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med 
Hyg;74: 76-80.  
Reports of the Ministry of Health, Gedaref State, Sudan. 
Reports of the Department of Medicine, Gadaref teaching hospital, Ministry of Health, Gedaref 
State, Sudan. 
Bryceson, Anthony ( 2001). Tropical Medicine & International Health. 6: 928-934. 
R. Badaro, E. Falcoff, F.S. Badaro, E.M. Carvalho, D. Pedral-Sampaio, A. Barral, J.S. Carvalho, 
M. Barral-Netto, M. Brandely, L. Silva, and et al.(1990). Treatment of visceral leishmaniasis with 
pentavalent antimony and interferon gamma. The new England Journal of medicine, 322:16-21. 
 
Singh, M. (2000). Health Care for Children in Afghanistan. Pediatrics 105: 160-160     
Sundar S, Jha TK, Thakur CP, et al.( 2002). Oral miltefosine for Indian visceral leishmaniasis. N Engl 
J Med, 347:1739-46. 
Seaman J, Mercer AJ, Sondorp E,(1996). The epidemic of visceral leishmaniasis in Western Upper 
Nile, Southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 25: 862–971.  
Schorscher JA, Goris M,(1992). Incrimination of Phlebotomus (Larroussius) orientalis as a vector of 
visceral leishmaniasis in western Upper Nile Province, southern Sudan. Trans R Soc Trop Med Hyg 
86: 622–623.  
Singh S, Gilman-Sachs A, Chang KP, Reed SG.(1995) Diagnostic and prognostic value of K39 
recombinant antigen in Indian leishmaniasis. J Parasitol;81: 1000-3.  
Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, et al.(2006). Rapid, 
noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic 
strip tests for detection of anti-K39 antibody. J Clin Microbiol;44: 251-3.  
Sundar, Shyam; Rai, Madhukar.(2002). Current Opinion in Infectious Diseases. Bmj. 15(6):593-598. 
 
Sundar, S., Jha, T.K., Thakur, C. P., Sinha, P. K., Bhattacharya, S. K. (2007). Injectable 
Paromomycin for Visceral Leishmaniasis in India. NEJM 356: 2571-2581. 
Sunagane N; Yoshinobu E; Murayama N; Terawaki Y; Kamimura N; Uruno T. (2005) 
Faculty of Pharmaceutical Sciences, Yakugaku Zasshi.   125(2):197-203 
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 89 -
Sakru N; Ozensoy Toz S; Korkmaz M; Kavakli T; Alkan MZ; Ozbel Y (2006). The infection risk of 
visceral leishmaniasis among household members of active patients. Parasitol Int.55(2):131-3 
Shyam Sundar, (2002). Drug resistance in Indian visceral leishmaniasis. Tropical 
medicine and international health, 6: 849-854. 
Shyam Sundar & Mitali Chatterjee. (2006). Visceral leishmaniasis - current therapeutic modalities. 
Indian J Med Res 123: 345-352. 
 
Thomson M, Connor S.(2000).Environmental information systems for the control of arthropod vectors 
of disease. Med Vet Entomol 14: 227–244.  
Thomson M, Elnaiem DA, Ashford RW, Conner S,(1999). Towards a kala-azar risk map for Sudan: 
mapping the potential distribution of Phlebotomus orientalis using digital data of environmental 
variables. Trop Med Int Health 4: 105–113.  
Thomson M, Connor S.(2000). Environmental information systems for the control of arthropod vectors 
of disease. Med Vet Entomol 14: 227–244.  
Thakur CP; Narayan S; Ranjan A.Balaji Utthan Sansthan. (2004). Epidemiological, clinical & 
pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med 
Res.120(3):166-72  
Thakur CP; Narayan S.Balaji Utthan Sansthan, (2004).A comparative evaluation of amphotericin 
B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. 
Ann Trop Med Parasitol. 98(2):129-38 
V. Vanlerberghe, G. Diap, P. J. Guerin, F. Meheus, S. Gerstl, P. Van der Stuyft and M. 
Boelaert.(2007) Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Tropical Medicine 
& International Health 12:2, 274–283 
V. Pintado and R. López-Vélez, (2002). HIV-associated visceral leishmaniasis clinical microbiology 
and infection, 7:291-300. 
Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J.(2003). The development of QUA-DAS: 
a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC 
Med Res Methodol;3: 25.  
Wikipedia information about fluconazole. (2002). GNU Free Documentation License. Eur J Emerg 
Med.9(2):175-7 
WHO: control of leishmaniasis; Report of a WHO expert committee.1990:793).  
Zijlstra EE, El Hassan AM, Ghalib HW, Ismael A,(1994). Endemic kala-azar in eastern Sudan: a 
longitudinal study on the incidence of clinical and subclinical disease and post–kala-azar-dermal 
leishmaniasis. Am J Trop Med Hyg 51: 826–836.  
Zeese W, Frank W,(1987). Present epidemiological situation of VL in the Republic of Sudan. Zentralbl 
Bakteriol Mikrobiol Hyg A 264: 414–421.  
Visceral leishmaniasis Combination therapy ( pentostam + fluconazole ) 
 
 
 
 
 - 90 -
Zijlstra EE, Daifalla NS, Kager PA, Khalil EA, El-Hassan AM, Reed SG, et al.(1998). rK39 enzyme-
linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab 
Immunol;5: 717-20.  
 
Zvulunov A., Klaus S., Vardy D., Alrajhi A. A., De Vol E. B., Maguire J. H. (2002). Fluconazole for 
the Treatment of Cutaneous Leishmaniasis. N Engl J Med.347:370  
 
 
 
 
